<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Hum Psychopharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Hum Psychopharmacol</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1099-1077</journal-id><journal-id journal-id-type="publisher-id">HUP</journal-id><journal-title-group><journal-title>Human Psychopharmacology</journal-title></journal-title-group><issn pub-type="ppub">0885-6222</issn><issn pub-type="epub">1099-1077</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26331440</article-id><article-id pub-id-type="pmc">5049604</article-id><article-id pub-id-type="doi">10.1002/hup.2500</article-id><article-id pub-id-type="publisher-id">HUP2500</article-id><article-id pub-id-type="other">HUP-14-0136.R1</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Articles</subject></subj-group></article-categories><title-group><article-title>Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors</article-title><alt-title alt-title-type="right-running-head">Duloxetine and <styled-content style="fixed-case">SSRIs</styled-content> Attributes</alt-title><alt-title alt-title-type="left-running-head">D. V. Sheehan <italic>et al.</italic></alt-title></title-group><contrib-group><contrib id="hup2500-cr-0001" contrib-type="author"><name><surname>Sheehan</surname><given-names>David V.</given-names></name><xref ref-type="aff" rid="hup2500-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="hup2500-cr-0002" contrib-type="author"><name><surname>Mancini</surname><given-names>Michele</given-names></name><xref ref-type="aff" rid="hup2500-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="hup2500-cr-0003" contrib-type="author"><name><surname>Wang</surname><given-names>Jianing</given-names></name><xref ref-type="aff" rid="hup2500-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="hup2500-cr-0004" contrib-type="author"><name><surname>Berggren</surname><given-names>Lovisa</given-names></name><xref ref-type="aff" rid="hup2500-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="hup2500-cr-0005" contrib-type="author"><name><surname>Cao</surname><given-names>Haijun</given-names></name><xref ref-type="aff" rid="hup2500-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="hup2500-cr-0006" contrib-type="author"><name><surname>Due&#x000f1;as</surname><given-names>H&#x000e9;ctor Jos&#x000e9;</given-names></name><xref ref-type="aff" rid="hup2500-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="hup2500-cr-0007" contrib-type="author" corresp="yes"><name><surname>Yue</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="hup2500-aff-0003">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="hup2500-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Morsani College of Medicine</named-content><institution>University of South Florida</institution><named-content content-type="city">Tampa</named-content><named-content content-type="country-part">Florida</named-content><country country="US">USA</country></aff><aff id="hup2500-aff-0002"><label><sup>2</sup></label><institution>Eli Lilly and Company</institution><named-content content-type="city">Bad Homburg</named-content><country country="DE">Germany</country></aff><aff id="hup2500-aff-0003"><label><sup>3</sup></label><institution>Lilly Suzhou Pharmaceutical Company Ltd</institution><named-content content-type="city">Shanghai</named-content><country country="CN">China</country></aff><aff id="hup2500-aff-0004"><label><sup>4</sup></label><institution>Lilly Emerging Markets</institution><named-content content-type="city">Mexico City</named-content><country country="MX">Mexico</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label>Correspondence to: L. Yue, Lilly Suzhou Pharmaceutical Company Ltd, Shanghai Branch, 21F, 1 Corporate Avenue, 222 Hu Bin Road, 200021, Shanghai, China. Tel: 8621&#x02010;2302&#x02010;0877; Fax: 8621&#x02010;2302&#x02010;1487 E&#x02010;mail: <email>yue_li_sh@lilly.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>01</day><month>9</month><year>2015</year></pub-date><volume>31</volume><issue>1</issue><issue-id pub-id-type="doi">10.1002/hup.v31.1</issue-id><fpage>53</fpage><lpage>63</lpage><history><date date-type="received"><day>19</day><month>11</month><year>2014</year></date><date date-type="rev-recd"><day>11</day><month>5</month><year>2015</year></date><date date-type="accepted"><day>10</day><month>7</month><year>2015</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2016 John Wiley & Sons, Ltd. <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2015 The Authors. <italic>Human Psychopharmacology: Clinical and Experimental</italic> published by John Wiley &#x00026; Sons, Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:HUP-31-53.pdf"/><abstract><sec id="hup2500-sec-0001"><title>Objective</title><p>We compared functional impairment outcomes assessed with Sheehan Disability Scale (SDS) after treatment with duloxetine versus selective serotonin reuptake inhibitors (SSRIs) in patients with major depressive disorder.</p></sec><sec id="hup2500-sec-0002"><title>Methods</title><p>Data were pooled from four randomized studies comparing treatment with duloxetine and SSRIs (three double blind and one open label). Analysis of covariance, with last&#x02010;observation&#x02010;carried&#x02010;forward approach for missing data, explored treatment differences between duloxetine and SSRIs on SDS changes during 8 to 12&#x02009;weeks of acute treatment for the intent&#x02010;to&#x02010;treat population. Logistic regression analysis examined the predictive capacity of baseline patient characteristics for remission in functional impairment (SDS total score&#x02009;&#x02264;&#x02009;6 and SDS item scores&#x02009;&#x02264;&#x02009;2) at endpoint.</p></sec><sec id="hup2500-sec-0003"><title>Results</title><p>Included were 2193 patients (duloxetine <italic>n</italic>&#x02009;=&#x02009;1029; SSRIs <italic>n</italic>&#x02009;=&#x02009;835; placebo <italic>n</italic>&#x02009;=&#x02009;329). Treatment with duloxetine and SSRIs resulted in significantly (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) greater improvements in the SDS total score versus treatment with placebo. Higher SDS (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) or 17&#x02010;item Hamilton Depression Rating Scale baseline scores (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) predicted lower probability of functional improvement after treatment with duloxetine or SSRIs. Female gender (<italic>p</italic>&#x02009;&#x02264;&#x02009;0.05) predicted higher probability of functional improvement after treatment with duloxetine or SSRIs.</p></sec><sec id="hup2500-sec-0004"><title>Conclusions</title><p>Treatment with SSRIs and duloxetine improved functional impairment in patients with major depressive disorder. Higher SDS or 17&#x02010;item Hamilton Depression Rating Scale baseline scores predicted less probability of SDS improvement; female gender predicted better improvement in functional impairment at endpoint. &#x000a9; 2015 The Authors. <italic>Human Psychopharmacology: Clinical and Experimental</italic> published by John Wiley &#x00026; Sons, Ltd.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="hup2500-kwd-0001">remission</kwd><kwd id="hup2500-kwd-0002">SDS</kwd><kwd id="hup2500-kwd-0003">MADRS</kwd><kwd id="hup2500-kwd-0004">HAMD&#x02010;17</kwd><kwd id="hup2500-kwd-0005">duloxetine</kwd><kwd id="hup2500-kwd-0006">SSRIs</kwd></kwd-group><funding-group><award-group><funding-source>Lilly Suzhou Pharmaceutical Company Ltd</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Eli Lilly and Company</funding-source></award-group></funding-group><counts><page-count count="11"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>hup2500</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2016</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.4 mode:remove_FC converted:04.10.2016</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="hup2500-cit-0000">
<string-name>
<surname>Sheehan</surname>, <given-names>D. V.</given-names>
</string-name>, <string-name>
<surname>Mancini</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Berggren</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Cao</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Due&#x000f1;as</surname>, <given-names>H. J.</given-names>
</string-name>, and <string-name>
<surname>Yue</surname>, <given-names>L.</given-names>
</string-name> (<year>2016</year>) <article-title>Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors</article-title>. <source>Hum. Psychopharmacol Clin Exp</source>, <volume>31</volume>: <fpage>44</fpage>&#x02013;<lpage>54</lpage>. doi: <ext-link ext-link-type="doi" xlink:href="10.1002/hup.2500">10.1002/hup.2500</ext-link>.</mixed-citation>
</p></notes></front><body><sec id="hup2500-sec-0005"><title>Introduction</title><p>Major depressive disorder (MDD) is often associated with functional impairments in affected patients (Papakostas, <xref rid="hup2500-bib-0019" ref-type="ref">2009</xref>; Snyder, <xref rid="hup2500-bib-0028" ref-type="ref">2013</xref>). These impairments have strong social and economic effects, frequently causing patients to miss work (Ryts&#x000e4;l&#x000e4; <italic>et al</italic>., <xref rid="hup2500-bib-0023" ref-type="ref">2005</xref>), experience difficulties in social relationships (Dunn <italic>et al</italic>., <xref rid="hup2500-bib-0004" ref-type="ref">2012</xref>) and report reduced family functioning (Weinstock <italic>et al</italic>., <xref rid="hup2500-bib-0030" ref-type="ref">2006</xref>).</p><p>Outcomes of antidepressant treatment in MDD vary greatly among individual patients. Proposed predictive factors of outcome include illness characteristics, comorbid mental disorders (van der Werff <italic>et al</italic>., <xref rid="hup2500-bib-0029" ref-type="ref">2010</xref>), genetic polymorphisms, brain metabolism and functional brain asymmetry (Papakostas and Fava, <xref rid="hup2500-bib-0020" ref-type="ref">2008</xref>). However, while many of those associations were linked to outcomes in depressive symptoms, their influence on functional outcomes in patients with MDD was not explored.</p><p>Nonetheless, there is increasing recognition of the importance of functional outcomes in patients with MDD. Frequently, functional impairments persist even when depressive symptoms are in remission (Nakano <italic>et al</italic>., <xref rid="hup2500-bib-0016" ref-type="ref">2008</xref>; Sheehan and Sheehan, <xref rid="hup2500-bib-0027" ref-type="ref">2008</xref>; Sheehan <italic>et al</italic>., <xref rid="hup2500-bib-0024" ref-type="ref">2011a</xref>). Nakano and colleagues (<xref rid="hup2500-bib-0016" ref-type="ref">2008</xref>) demonstrated that executive dysfunction remained even when patients with MDD were in remission of their depressive symptoms. Similarly, Sheehan and colleagues (<xref rid="hup2500-bib-0024" ref-type="ref">2011a</xref>) analysed three MDD studies and four generalized anxiety disorder studies and found that in neither patient group did symptom remission and functional remission move in tandem for every patient.</p><p>The neurotransmitter norepinephrine plays a role in the regulation of cognition, motivation and intellect (Moret and Briley, <xref rid="hup2500-bib-0015" ref-type="ref">2011</xref>). Duloxetine hydrochloride (hereafter duloxetine) is a serotonin and norepinephrine reuptake inhibitor, approved for the treatment of MDD (Eli Lilly and Company, <xref rid="hup2500-bib-0005" ref-type="ref">2014</xref>).</p><p>A validated and accepted measure of functional outcome in MDD is the Sheehan Disability Scale (SDS) (Sheehan <italic>et al</italic>., <xref rid="hup2500-bib-0026" ref-type="ref">1996</xref>; Sheehan and Sheehan, <xref rid="hup2500-bib-0027" ref-type="ref">2008</xref>). This three&#x02010;item scale assesses functional impairments associated with work/school, social life and leisure activities, and family life and home responsibilities in patients with MDD, with higher scores indicating greater functional impairment (Sheehan <italic>et al</italic>., <xref rid="hup2500-bib-0026" ref-type="ref">1996</xref>). The SDS has been successfully used to assess changes in functional impairment in patients with MDD during treatment with duloxetine in several clinical trials (Raskin <italic>et al</italic>., <xref rid="hup2500-bib-0021" ref-type="ref">2003</xref>; Detke <italic>et al</italic>., <xref rid="hup2500-bib-0002" ref-type="ref">2004</xref>; Due&#x000f1;as <italic>et al</italic>., <xref rid="hup2500-bib-0003" ref-type="ref">2011</xref>; Gaynor <italic>et al</italic>., <xref rid="hup2500-bib-0007" ref-type="ref">2011a</xref>, <xref rid="hup2500-bib-0008" ref-type="ref">2011b</xref>; Sheehan <italic>et al</italic>., <xref rid="hup2500-bib-0025" ref-type="ref">2011b</xref>; Mancini <italic>et al</italic>., <xref rid="hup2500-bib-0012" ref-type="ref">2012</xref>; Martinez <italic>et al</italic>., <xref rid="hup2500-bib-0013" ref-type="ref">2012</xref>; Oakes <italic>et al</italic>., <xref rid="hup2500-bib-0018" ref-type="ref">2012</xref>).</p><p>The objective of the current study was to compare functional outcomes as assessed with the SDS between treatment with duloxetine and selective serotonin reuptake inhibitors (SSRIs) in patients with MDD by using pooled data from all randomized clinical studies comparing duloxetine with SSRIs that used the SDS to measure patients' functioning and that were sponsored by Eli Lilly and Company. We also explored the roles of patient demographics, disorder duration and baseline symptom severity as predictors of functional outcomes in patients with MDD.</p></sec><sec id="hup2500-sec-0006"><title>Methods</title><p>We pooled data from four randomized clinical studies that compared the efficacy of duloxetine with an SSRI in the treatment of MDD, as defined by the <italic>Diagnostic and Statistical Manual of Mental Disorders</italic>, <italic>Fourth Edition</italic> (Table&#x000a0;<xref rid="hup2500-tbl-0001" ref-type="table-wrap">1</xref>). The dataset included three placebo&#x02010;controlled, double&#x02010;blind clinical studies (study acronyms of HMAYa, HMAYb and HMCR) and one open&#x02010;label clinical study (study acronym of HMFT). All studies included an acute treatment phase of at least 8&#x02009;weeks, compared treatment with duloxetine versus SSRIs and used the SDS to assess the effect of treatment on patient functioning.</p><table-wrap id="hup2500-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Clinical study designs</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="center" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Study acronym</th><th align="center" valign="bottom" rowspan="1" colspan="1">Design</th><th align="center" valign="bottom" rowspan="1" colspan="1">Treatment arms</th><th align="center" valign="bottom" rowspan="1" colspan="1">Mean dose(mg) (SD)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Length of acute phase (weeks)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Baseline symptom thresholds</th></tr></thead><tbody valign="top"><tr><td rowspan="4" align="left" valign="top" colspan="1">HMAYa</td><td rowspan="4" align="left" valign="top" colspan="1">Randomized, double blind and fixed dose</td><td align="left" valign="top" rowspan="1" colspan="1">DLX (40 or 60&#x02009;mg BID)</td><td rowspan="4" align="left" valign="top" colspan="1">NA</td><td rowspan="4" align="char" char="." valign="top" colspan="1">9</td><td rowspan="3" align="left" valign="top" colspan="1">HAMD&#x02010;17 total score&#x02009;&#x02265;&#x02009;15</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PRX (20&#x02009;mg QD)</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">PLB</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CGI&#x02010;S&#x02009;&#x02265;&#x02009;4</td></tr><tr><td rowspan="4" align="left" valign="top" colspan="1">HMAYb</td><td rowspan="4" align="left" valign="top" colspan="1">Randomized, double blind and fixed dose</td><td rowspan="2" align="left" valign="top" colspan="1">DLX (40 or 60&#x02009;mg BID)</td><td rowspan="4" align="left" valign="top" colspan="1">NA</td><td rowspan="4" align="char" char="." valign="top" colspan="1">9</td><td align="left" valign="top" rowspan="1" colspan="1">HAMD&#x02010;17 total score&#x02009;&#x02265;&#x02009;15</td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">CGI&#x02010;S&#x02009;&#x02265;&#x02009;4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PRX (20&#x02009;mg QD)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PLB</td></tr><tr><td rowspan="4" align="left" valign="top" colspan="1">HMCR</td><td rowspan="4" align="left" valign="top" colspan="1">Randomized, double blind and fixed dose</td><td align="left" valign="top" rowspan="1" colspan="1">DLX (60, 90 and 120&#x02009;mg QD)</td><td rowspan="4" align="left" valign="top" colspan="1">NA</td><td rowspan="4" align="char" char="." valign="top" colspan="1">8</td><td rowspan="3" align="left" valign="top" colspan="1">MADRS&#x02009;&#x02265;&#x02009;22</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ESC (10 and 20&#x02009;mg QD)</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">PLB</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CGI&#x02010;S&#x02009;&#x02265;&#x02009;4</td></tr><tr><td rowspan="6" align="left" valign="top" colspan="1">HMFT</td><td rowspan="6" align="left" valign="top" colspan="1">Randomized, open label and flexible dose</td><td align="left" valign="top" rowspan="1" colspan="1">DLX (60&#x02013;120&#x02009;mg QD)</td><td align="left" valign="top" rowspan="1" colspan="1">DLX&#x02009;=&#x02009;70.8 (22.0)</td><td rowspan="6" align="char" char="." valign="top" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">PHQ&#x02010;9&#x02009;&#x02265;&#x02009;16</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Generic SSRIs</td><td align="left" valign="top" rowspan="1" colspan="1">CIT&#x02009;=&#x02009;33.1 (9.1)</td><td rowspan="5" align="left" valign="top" colspan="1">QIDS&#x02010;SR&#x02009;&#x02265;&#x02009;20</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CIT (20&#x02013;40&#x02009;mg QD)</td><td align="left" valign="top" rowspan="1" colspan="1">FLX&#x02009;=&#x02009;42.3 (16.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FLX (20&#x02013;80&#x02009;mg QD)</td><td align="left" valign="top" rowspan="1" colspan="1">PRX&#x02009;=&#x02009;29.0 (8.4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PRX (20&#x02013;50&#x02009;mg QD)</td><td rowspan="2" align="left" valign="top" colspan="1">SER&#x02009;=&#x02009;109.0 (38.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SER (50&#x02013;200&#x02009;mg QD)</td></tr></tbody></table><table-wrap-foot><fn id="hup2500-note-0001"><p>BID, twice daily; CIT, citalopram; DLX, duloxetine; CGI&#x02010;S, Clinical Global Impression&#x02010;Severity; ESC, escitalopram; FLX, fluoxetine; HAMD&#x02010;17, 17&#x02010;item Hamilton Depression Rating Scale; MADRS, Montgomery&#x02013;&#x000c5;sberg Depression Rating Scale; NA, not applicable; PHQ&#x02010;9, Patient Health Questionnaire Depression Scale; PLB, placebo; PRX, paroxetine; QD, once daily; QIDS&#x02010;SR, 16&#x02010;item Quick Inventory of Depressive Symptomatology (self&#x02010;report); SD, standard deviation; SER, sertraline.</p></fn></table-wrap-foot></table-wrap><p>Among all randomized clinical studies included in the Eli Lilly and Company integrated database for duloxetine efficacy in MDD (cut&#x02010;off date 18 June 2014), 19 studies administered the SDS. Among these 19 studies, only eight studies included treatment comparisons between duloxetine and active compounds; of these eight studies, two studies did not use treatment with SSRIs as an active control, one study focused on the timing of intervention strategies and one study only included MDD patients with residual apathy but without depressed mood.</p><p>Prior to patient enrolment, the appropriate institutional review boards reviewed and approved the study protocols. All patients provided written informed consent before receiving any study therapy or undergoing any study procedure, and the studies were performed according to Good Clinical Practice guidelines and the Declaration of Helsinki.</p><sec id="hup2500-sec-0007"><title>Baseline and treatment assessment scales</title><sec id="hup2500-sec-0008"><title>Sheehan Disability Scale (Sheehan <italic>et al</italic>., <xref rid="hup2500-bib-0026" ref-type="ref">1996</xref>)</title><p>The SDS is a disability or functional impairment scale that uses a discan metric. This discan metric anchors the response options by simultaneously using visual&#x02013;spatial, numeric and verbal descriptive anchors to assess disability or functional impairment across three domains: work/school, social life/leisure activities and family life/home responsibilities. Each domain is scored from 0 (<italic>not at all</italic>) to 10 (<italic>very severely</italic>). The three domains can be summarized to evaluate global functional impairment by adding the scores of each of the three domains, resulting in global SDS score ranges from 0 (<italic>unimpaired</italic>) to 30 (<italic>highly impaired</italic>) (Sheehan <italic>et al</italic>., <xref rid="hup2500-bib-0026" ref-type="ref">1996</xref>; Sheehan and Sheehan, <xref rid="hup2500-bib-0027" ref-type="ref">2008</xref>). Functional remission was defined as SDS&#x02009;&#x02264;&#x02009;6 at endpoint (Sheehan and Sheehan, <xref rid="hup2500-bib-0027" ref-type="ref">2008</xref>; Sheehan <italic>et al</italic>., <xref rid="hup2500-bib-0024" ref-type="ref">2011a</xref>).</p></sec><sec id="hup2500-sec-0009"><title>Montgomery&#x02013;&#x000c5;sberg Depression Rating Scale (Montgomery and Asberg, <xref rid="hup2500-bib-0014" ref-type="ref">1979</xref>)</title><p>The Montgomery&#x02013;&#x000c5;sberg Depression Rating Scale (MADRS) is a 10&#x02010;item scale, with each item rated from 0 to 6. The MADRS total score is the sum of the 10 items and ranges from 0 (<italic>not at all depressed</italic>) to 60 (<italic>severely depressed</italic>) (Montgomery and Asberg, <xref rid="hup2500-bib-0014" ref-type="ref">1979</xref>).</p></sec><sec id="hup2500-sec-0010"><title>Seventeen&#x02010;item Hamilton Depression Rating Scale (Hamilton, <xref rid="hup2500-bib-0011" ref-type="ref">1960</xref>)</title><p>The 17&#x02010;item Hamilton Depression Rating Scale (HAMD&#x02010;17) assesses the severity of depression and produces a total score ranging from 0 (<italic>not at all depressed</italic>) to 52 (<italic>severely depressed</italic>) (Hamilton, <xref rid="hup2500-bib-0011" ref-type="ref">1960</xref>).</p></sec><sec id="hup2500-sec-0011"><title>Clinical Global Impressions of Severity Scale (Guy, <xref rid="hup2500-bib-0010" ref-type="ref">1976</xref>)</title><p>The physician&#x02010;administered Clinical Global Impressions of Severity Scale records the severity of illness at the time of assessment. The score ranges from 1 (<italic>normal, not at all ill</italic>) to 7 (<italic>among the most extremely ill patients</italic>).</p></sec></sec><sec id="hup2500-sec-0012"><title>Statistical analyses</title><p>Baseline demographics and illness assessment data were summarized for all patients included in the current study. Analysis of covariance (ANCOVA) with a last&#x02010;observation&#x02010;carried&#x02010;forward approach for missing data was used to explore treatment differences between duloxetine and SSRIs on SDS changes during 8 to 12&#x02009;weeks of acute treatment for the intent&#x02010;to&#x02010;treat population, including all patients for whom baseline assessment and at least one post&#x02010;baseline assessment were available. The ANCOVA models with treatment as fixed effect and baseline SDS total score as covariate were calculated for each study. Effect sizes in each model were calculated for least squares (LS) mean differences between treatment groups divided by the standard deviation (SD) of the residuals provided by the model of this study. Overall, LS mean estimates and effect sizes were calculated as a weighted mean of the corresponding estimates in all studies, with weights based on within&#x02010;study variance, assuming a fixed study effect. <italic>p</italic>&#x02010;values were derived from <italic>t</italic>&#x02010;test for LS mean differences. No corrections of multiple comparisons were applied.</p><p>Logistic regression analyses were performed to determine odds ratios (ORs) for SDS total scores &#x02264;6 versus &#x0003e;6 and for SDS individual item scores &#x02264;2 versus &#x0003e;2. A logistic regression model was estimated for each study with treatment as fixed effect, and baseline SDS total score or baseline SDS item score as covariate. All ORs were calculated via a meta&#x02010;analysis approach as a weighted mean of the corresponding log(OR) in all individual studies with weights based on the variance of log(OR).</p><p>Logistic regression analyses were also performed to determine potential predictors of remission in functional impairment (SDS total scores &#x02264;6 vs &#x0003e;6 and SDS individual item scores &#x02264;2 vs &#x0003e;2). Study, treatment, SDS baseline score, HAMD&#x02010;17 baseline score, gender, age, race, number of previous episodes and duration of the current episode were included in the analysis model.</p><p>Numbers needed to treat (<italic>NNT</italic>s) to reach an SDS total score of &#x02264;6 at last&#x02010;observation&#x02010;carried&#x02010;forward endpoint for the pooled dataset for treatment with duloxetine and for treatment with SSRIs were determined by using the following formula:
<disp-formula id="hup2500-disp-0001"><mml:math id="nlm-math-1"><mml:mi>N</mml:mi><mml:mi>N</mml:mi><mml:mi>T</mml:mi><mml:mo>=</mml:mo><mml:mfrac bevelled="true"><mml:mn>1</mml:mn><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mtext>active&#x000a0;treatment&#x000a0;event&#x000a0;rate</mml:mtext><mml:mo>&#x02212;</mml:mo><mml:mtext>placebo&#x000a0;event&#x000a0;rate</mml:mtext></mml:mrow></mml:mfenced><mml:mspace width="0.25em"/></mml:mrow></mml:mfrac></mml:math></disp-formula>
</p></sec></sec><sec id="hup2500-sec-0013"><title>Results</title><sec id="hup2500-sec-0014"><title>Patient baseline characteristics</title><p>Included in the analyses were 2193 patients (duloxetine <italic>n</italic>&#x02009;=&#x02009;1029; SSRIs <italic>n</italic>&#x02009;=&#x02009;835; placebo <italic>n</italic>&#x02009;=&#x02009;329). Most patients were female (duloxetine&#x02009;=&#x02009;67.0%, SSRI&#x02009;=&#x02009;68.5% and placebo&#x02009;=&#x02009;67.2%). The mean ages of duloxetine, SSRI and placebo groups were 43.5 (SD: 12.1), 43.7 (SD: 12.6) and 43.5 (SD: 11.6) years, respectively (<xref rid="hup2500-supitem-0001" ref-type="supplementary-material">Supporting information Table&#x000a0;1</xref>). At baseline, patients displayed moderate illness severity with mean Clinical Global Impressions of Severity scores ranging from 4.2 to 4.3 and mean SDS total scores ranging from 20.0 to 20.9 across treatment groups (<xref rid="hup2500-supitem-0001" ref-type="supplementary-material">Supporting information Table&#x000a0;2</xref>).</p></sec><sec id="hup2500-sec-0015"><title>Patient disposition</title><p>The study completion rates for duloxetine, SSRIs and placebo were 78.1%, 78.2% and 79.9%, respectively. The most common reasons for early discontinuation were lost to follow&#x02010;up (duloxetine, 6.3%; SSRI, 7.1%; placebo, 4.9%) and adverse events (duloxetine, 5.2%; SSRI, 3.6%; placebo, 3.6%).</p></sec><sec id="hup2500-sec-0016"><title>Study medication doses</title><p>In study HMAY, patients were randomized to duloxetine 60&#x02009;mg twice daily (BID), duloxetine 40&#x02009;mg BID, placebo or paroxetine 20&#x02009;mg once daily (QD) for the 8&#x02010;week acute treatment period. In study HMCR, patients were randomized to duloxetine 60&#x02009;mg QD, escitalopram 10&#x02009;mg QD or placebo. In study HMFT, patients were randomized to flexible&#x02010;dosed duloxetine or SSRI (citalopram, fluoxetine, paroxetine or sertraline; mean daily doses are displayed in Table&#x000a0;<xref rid="hup2500-tbl-0001" ref-type="table-wrap">1</xref>).</p><p>Paroxetine 20&#x02009;mg QD (GlaxoSmithKline, <xref rid="hup2500-bib-0009" ref-type="ref">2013</xref>), escitalopram 10&#x02009;mg QD (Forest Laboratories, Inc., <xref rid="hup2500-bib-0006" ref-type="ref">2009</xref>) and duloxetine 40&#x02009;mg/day (Eli Lilly and Company, <xref rid="hup2500-bib-0005" ref-type="ref">2014</xref>) are the minimum effective doses approved for the treatment of MDD. In some of the studies, the dose of duloxetine used was higher than the minimum effective dose approved for duloxetine (i.e. &#x0003e;40&#x02009;mg/day), while in those same studies, the dose of the comparator SSRI was the minimum approved dose.</p></sec><sec id="hup2500-sec-0017"><title>Change from baseline in Sheehan Disability Scale total scores</title><p>Patients in all treatment groups displayed significantly (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) reduced SDS total scores at endpoint (Table&#x000a0;<xref rid="hup2500-tbl-0002" ref-type="table-wrap">2</xref>) compared with baseline, and both treatment with duloxetine and treatment with SSRIs resulted in statistically significantly (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) greater reductions in SDS total scores compared with placebo. No significant differences in change from baseline in SDS total scores were observed between treatment with duloxetine and treatment with SSRIs (Table&#x000a0;<xref rid="hup2500-tbl-0002" ref-type="table-wrap">2</xref>).</p><table-wrap id="hup2500-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Sheehan Disability Scale total and individual item scores at endpoint&#x02014;data from studies HMAYa, HMAYb, HMCR and HMFT; all randomized patients</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" align="left" valign="bottom" colspan="1">Population</th><th colspan="2" align="center" valign="bottom" rowspan="1">DLX</th><th colspan="2" align="center" valign="bottom" rowspan="1">SSRI</th><th colspan="2" align="center" valign="bottom" rowspan="1">PLB</th><th align="center" valign="bottom" rowspan="1" colspan="1">DLX vs SSRI</th><th align="center" valign="bottom" rowspan="1" colspan="1">DLX vs PLB</th><th align="center" valign="bottom" rowspan="1" colspan="1">SSRI vs PLB</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">LSMean (SE)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">LSMean (SE)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">LSMean (SE)</th><th align="center" valign="bottom" rowspan="1" colspan="1">LSMean (effect size)</th><th align="center" valign="bottom" rowspan="1" colspan="1">LSMean (effect size)</th><th align="center" valign="bottom" rowspan="1" colspan="1">LSMean (effect size)</th></tr></thead><tbody valign="top"><tr><td colspan="10" align="left" valign="top" rowspan="1">Total</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">All patients<xref ref-type="fn" rid="hup2500-note-0004">a</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">847</td><td align="char" valign="top" rowspan="1" colspan="1">12.3 (0.3)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">669</td><td align="char" valign="top" rowspan="1" colspan="1">12.9 (0.3)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">284</td><td align="char" valign="top" rowspan="1" colspan="1">14.4 (0.4)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">&#x02212;0.4 (&#x02212;0.1)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;1.9 (&#x02212;0.3)<xref ref-type="fn" rid="hup2500-note-0010">###</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;1.7 (&#x02212;0.2)<xref ref-type="fn" rid="hup2500-note-0011">##</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">HAMD&#x02010;17&#x02009;&#x02264;&#x02009;22<xref ref-type="fn" rid="hup2500-note-0005">b</xref>, <xref ref-type="fn" rid="hup2500-note-0006">c</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">529</td><td align="char" valign="top" rowspan="1" colspan="1">12.3 (0.3)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">385</td><td align="char" valign="top" rowspan="1" colspan="1">12.8 (0.4)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">233</td><td align="char" valign="top" rowspan="1" colspan="1">14.2 (0.5)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">&#x02212;0.2 (0.0)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;1.8 (&#x02212;0.2)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;1.6 (&#x02212;0.2)<xref ref-type="fn" rid="hup2500-note-0012">#</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">HAMD&#x02010;17&#x02009;&#x0003e;&#x02009;22<xref ref-type="fn" rid="hup2500-note-0005">b</xref>, <xref ref-type="fn" rid="hup2500-note-0006">c</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">318</td><td align="char" valign="top" rowspan="1" colspan="1">12.2 (0.5)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">284</td><td align="char" valign="top" rowspan="1" colspan="1">13.1 (0.5)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">51</td><td align="char" valign="top" rowspan="1" colspan="1">15.1 (1.0)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.7 (&#x02212;0.1)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;2.4 (&#x02212;0.3)<xref ref-type="fn" rid="hup2500-note-0012">#</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;2.1 (&#x02212;0.3)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">MADRS&#x02009;&#x02264;&#x02009;30<xref ref-type="fn" rid="hup2500-note-0006">c</xref>, <xref ref-type="fn" rid="hup2500-note-0007">d</xref>, <xref ref-type="fn" rid="hup2500-note-0008">e</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">434</td><td align="char" valign="top" rowspan="1" colspan="1">12.1 (0.4)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">269</td><td align="char" valign="top" rowspan="1" colspan="1">12.2 (0.5)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">211</td><td align="char" valign="top" rowspan="1" colspan="1">14.2 (0.5)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.1 (0.02)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;2.1 (&#x02212;0.3)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;2.2 (&#x02212;0.3)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">MADRS&#x02009;&#x0003e;&#x02009;30<xref ref-type="fn" rid="hup2500-note-0005">b</xref>, <xref ref-type="fn" rid="hup2500-note-0006">c</xref>, <xref ref-type="fn" rid="hup2500-note-0007">d</xref>, <xref ref-type="fn" rid="hup2500-note-0008">e</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">138</td><td align="char" valign="top" rowspan="1" colspan="1">13.9 (0.6)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">121</td><td align="char" valign="top" rowspan="1" colspan="1">15.0 (0.7)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">73</td><td align="char" valign="top" rowspan="1" colspan="1">15.1 (0.9)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;1.0 (&#x02212;0.1)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;1.3 (&#x02212;0.2)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.5 (&#x02212;0.1)</td></tr><tr><td colspan="10" align="left" valign="top" rowspan="1">Item 1</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">All patients</td><td align="char" valign="top" rowspan="1" colspan="1">847</td><td align="char" valign="top" rowspan="1" colspan="1">3.9 (0.1)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">669</td><td align="char" valign="top" rowspan="1" colspan="1">4.1 (0.1)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">284</td><td align="char" valign="top" rowspan="1" colspan="1">4.8 (0.2)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.2 (&#x02212;0.1)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.8 (&#x02212;0.3)<xref ref-type="fn" rid="hup2500-note-0010">###</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.7 (&#x02212;0.3)<xref ref-type="fn" rid="hup2500-note-0010">###</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">HAMD&#x02010;17&#x02009;&#x02264;&#x02009;22<xref ref-type="fn" rid="hup2500-note-0005">b</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">529</td><td align="char" valign="top" rowspan="1" colspan="1">3.9 (0.1)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">385</td><td align="char" valign="top" rowspan="1" colspan="1">4.0 (0.1)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">233</td><td align="char" valign="top" rowspan="1" colspan="1">4.7 (0.2)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.1 (0.0)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.7 (&#x02212;0.3)<xref ref-type="fn" rid="hup2500-note-0010">###</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.6 (&#x02212;0.2)<xref ref-type="fn" rid="hup2500-note-0011">##</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">HAMD&#x02010;17&#x02009;&#x0003e;&#x02009;22<xref ref-type="fn" rid="hup2500-note-0005">b</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">318</td><td align="char" valign="top" rowspan="1" colspan="1">3.8 (0.2)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">284</td><td align="char" valign="top" rowspan="1" colspan="1">4.3 (0.2)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">51</td><td align="char" valign="top" rowspan="1" colspan="1">5.2 (0.4)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.5 (&#x02212;0.2)<xref ref-type="fn" rid="hup2500-note-0012">#</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;1.1 (&#x02212;0.4)<xref ref-type="fn" rid="hup2500-note-0011">##</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;1.1 (&#x02212;0.4)<xref ref-type="fn" rid="hup2500-note-0012">#</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">MADRS&#x02009;&#x02264;&#x02009;30<xref ref-type="fn" rid="hup2500-note-0004">a</xref>, <xref ref-type="fn" rid="hup2500-note-0005">b</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">434</td><td align="char" valign="top" rowspan="1" colspan="1">3.9 (0.1)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">269</td><td align="char" valign="top" rowspan="1" colspan="1">3.9 (0.2)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">211</td><td align="char" valign="top" rowspan="1" colspan="1">4.7 (0.2)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.1 (0.0)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.8 (&#x02212;0.3)<xref ref-type="fn" rid="hup2500-note-0010">###</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.8 (&#x02212;0.3)<xref ref-type="fn" rid="hup2500-note-0010">###</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">MADRS&#x02009;&#x0003e;&#x02009;30<xref ref-type="fn" rid="hup2500-note-0004">a</xref>, <xref ref-type="fn" rid="hup2500-note-0005">b</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">138</td><td align="char" valign="top" rowspan="1" colspan="1">4.2 (0.2)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">121</td><td align="char" valign="top" rowspan="1" colspan="1">4.6 (0.2)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">73</td><td align="char" valign="top" rowspan="1" colspan="1">4.9 (0.3)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.4 (&#x02212;0.1)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.7 (&#x02212;0.3)<xref ref-type="fn" rid="hup2500-note-0012">#</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.4 (&#x02212;0.2)</td></tr><tr><td colspan="10" align="left" valign="top" rowspan="1">Item 2</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">All patients</td><td align="left" valign="top" rowspan="1" colspan="1">1023</td><td align="left" valign="top" rowspan="1" colspan="1">4.1 (0.1)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">834</td><td align="char" valign="top" rowspan="1" colspan="1">4.3 (0.1)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">328</td><td align="char" valign="top" rowspan="1" colspan="1">4.9 (0.2)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.2 (&#x02212;0.1)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.7 (&#x02212;0.3)<xref ref-type="fn" rid="hup2500-note-0010">###</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.7 (&#x02212;0.3)<xref ref-type="fn" rid="hup2500-note-0010">###</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">HAMD&#x02010;17&#x02009;&#x02264;&#x02009;22<xref ref-type="fn" rid="hup2500-note-0005">b</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">615</td><td align="left" valign="top" rowspan="1" colspan="1">4.1 (0.1)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">456</td><td align="char" valign="top" rowspan="1" colspan="1">4.2 (0.1)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">262</td><td align="char" valign="top" rowspan="1" colspan="1">4.9 (0.2)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0 (0.0)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.7 (&#x02212;0.2)<xref ref-type="fn" rid="hup2500-note-0011">##</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.7 (&#x02212;0.3)<xref ref-type="fn" rid="hup2500-note-0011">##</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">HAMD&#x02010;17&#x02009;&#x0003e;&#x02009;22<xref ref-type="fn" rid="hup2500-note-0005">b</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">406</td><td align="left" valign="top" rowspan="1" colspan="1">4.1 (0.1)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">378</td><td align="char" valign="top" rowspan="1" colspan="1">4.5 (0.2)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">66</td><td align="char" valign="top" rowspan="1" colspan="1">5.3 (0.3)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.4 (&#x02212;0.1)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.7 (&#x02212;0.3)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.7 (&#x02212;0.3)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">MADRS&#x02009;&#x02264;&#x02009;30<xref ref-type="fn" rid="hup2500-note-0004">a</xref>, <xref ref-type="fn" rid="hup2500-note-0005">b</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">492</td><td align="left" valign="top" rowspan="1" colspan="1">4.0 (0.1)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">310</td><td align="char" valign="top" rowspan="1" colspan="1">4.0 (0.2)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">242</td><td align="char" valign="top" rowspan="1" colspan="1">4.8 (0.2)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.2 (0.1)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.7 (&#x02212;0.2)<xref ref-type="fn" rid="hup2500-note-0011">##</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.8 (&#x02212;0.3)<xref ref-type="fn" rid="hup2500-note-0010">###</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">MADRS&#x02009;&#x0003e;&#x02009;30<xref ref-type="fn" rid="hup2500-note-0004">a</xref>, <xref ref-type="fn" rid="hup2500-note-0005">b</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">164</td><td align="left" valign="top" rowspan="1" colspan="1">4.7 (0.2)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">147</td><td align="char" valign="top" rowspan="1" colspan="1">5.0 (0.2)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">86</td><td align="char" valign="top" rowspan="1" colspan="1">5.4 (0.3)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.2 (&#x02212;0.1)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.8 (&#x02212;0.3)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.6 (&#x02212;0.2)</td></tr><tr><td colspan="10" align="left" valign="top" rowspan="1">Item 3</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">All patients<xref ref-type="fn" rid="hup2500-note-0004">a</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">1024</td><td align="char" valign="top" rowspan="1" colspan="1">4.0 (0.1)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">834</td><td align="char" valign="top" rowspan="1" colspan="1">4.2 (0.1)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">329</td><td align="char" valign="top" rowspan="1" colspan="1">4.6 (0.1)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.1 (0.0)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.5 (&#x02212;0.2)<xref ref-type="fn" rid="hup2500-note-0011">##</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.6 (&#x02212;0.2)<xref ref-type="fn" rid="hup2500-note-0011">##</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">HAMD&#x02010;17&#x02009;&#x02264;&#x02009;22<xref ref-type="fn" rid="hup2500-note-0005">b</xref>, <xref ref-type="fn" rid="hup2500-note-0006">c</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">615</td><td align="char" valign="top" rowspan="1" colspan="1">4.0 (0.1)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">456</td><td align="char" valign="top" rowspan="1" colspan="1">4.1 (0.1)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">263</td><td align="char" valign="top" rowspan="1" colspan="1">4.6 (0.2)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.1 (0.0)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.5 (&#x02212;0.2)<xref ref-type="fn" rid="hup2500-note-0012">#</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.6 (&#x02212;0.2)<xref ref-type="fn" rid="hup2500-note-0011">##</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">HAMD&#x02010;17&#x02009;&#x0003e;&#x02009;22<xref ref-type="fn" rid="hup2500-note-0005">b</xref>, <xref ref-type="fn" rid="hup2500-note-0006">c</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">407</td><td align="char" valign="top" rowspan="1" colspan="1">4.0 (0.1)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">378</td><td align="char" valign="top" rowspan="1" colspan="1">4.4 (0.1)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">66</td><td align="char" valign="top" rowspan="1" colspan="1">4.8 (0.3)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.3 (&#x02212;0.1)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.5 (&#x02212;0.2)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.7 (&#x02212;0.3)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">MADRS&#x02009;&#x02264;&#x02009;30<xref ref-type="fn" rid="hup2500-note-0006">c</xref>, <xref ref-type="fn" rid="hup2500-note-0007">d</xref>, <xref ref-type="fn" rid="hup2500-note-0008">e</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">492</td><td align="char" valign="top" rowspan="1" colspan="1">3.9 (0.1)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">310</td><td align="char" valign="top" rowspan="1" colspan="1">3.9 (0.2)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">243</td><td align="char" valign="top" rowspan="1" colspan="1">4.5 (0.2)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.2 (0.1)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.6 (&#x02212;0.2)<xref ref-type="fn" rid="hup2500-note-0011">##</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.7 (&#x02212;0.3)<xref ref-type="fn" rid="hup2500-note-0011">##</xref>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">MADRS&#x02009;&#x0003e;&#x02009;30<xref ref-type="fn" rid="hup2500-note-0006">c</xref>, <xref ref-type="fn" rid="hup2500-note-0007">d</xref>, <xref ref-type="fn" rid="hup2500-note-0008">e</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">164</td><td align="char" valign="top" rowspan="1" colspan="1">4.7 (0.2)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">147</td><td align="char" valign="top" rowspan="1" colspan="1">4.9 (0.2)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">86</td><td align="char" valign="top" rowspan="1" colspan="1">5.0 (0.3)<xref ref-type="fn" rid="hup2500-note-0009">***</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0 (0.0)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.3 (&#x02212;0.1)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.3 (&#x02212;0.1)</td></tr></tbody></table><table-wrap-foot><fn id="hup2500-note-0002"><p>Effect sizes in each model were calculated for LSMean differences, divided by the standard deviation of the residuals provided by the model of this group. Overall LSMean estimates and effect sizes were calculated as a weighted mean of the corresponding estimates in all groups, with weights based on within&#x02010;group variance, assuming a fixed group effect. <italic>p</italic>&#x02010;values were derived from <italic>t</italic>&#x02010;test for LSMean differences.</p></fn><fn id="hup2500-note-0003"><p>DLX, duloxetine; HAMD&#x02010;17, 17&#x02010;item Hamilton Depression Rating Scale; LSMean, least squares mean; MADRS, Montgomery&#x02013;&#x000c5;sberg Depression Rating Scale; <italic>n</italic>, number of affected patients; PLB, placebo; SE, standard error; SSRI, selective serotonin reuptake inhibitor; ANCOVA, analysis of covariance; SDS, Sheehan Disability Scale.</p></fn><fn id="hup2500-note-0004"><label>a</label><p>One ANCOVA model was calculated for each study with treatment as fixed effect and baseline SDS total score as covariate.</p></fn><fn id="hup2500-note-0005"><label>b</label><p>One ANCOVA model was calculated for each group with treatment, HAMD&#x02010;17 total score at baseline (&#x02264;22/&#x0003e;22), and their interaction as fixed effect and baseline SDS total score as covariate.</p></fn><fn id="hup2500-note-0006"><label>c</label><p>Baseline score.</p></fn><fn id="hup2500-note-0007"><label>d</label><p>One ANCOVA model was calculated for each group with treatment, MADRS total score at baseline (&#x02264;30/&#x0003e;30), and their interaction as fixed effect and baseline SDS total score as covariate.</p></fn><fn id="hup2500-note-0008"><label>e</label><p>Not collected in HMFT.</p></fn><fn id="hup2500-note-0009"><label>***</label><p>
<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 versus baseline;</p></fn><fn id="hup2500-note-0010"><label>###</label><p>
<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 versus comparator;</p></fn><fn id="hup2500-note-0011"><label>##</label><p>
<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 versus comparator;</p></fn><fn id="hup2500-note-0012"><label>#</label><p>
<italic>p</italic>&#x02009;&#x02264;&#x02009;0.05 versus comparator.</p></fn></table-wrap-foot></table-wrap></sec><sec id="hup2500-sec-0018"><title>Change from baseline in Sheehan Disability Scale total scores&#x02014;subgroup analyses</title><p>When patients were grouped by baseline illness severity (HAMD&#x02010;17 &#x02264;22 vs &#x0003e;22), SDS total endpoint scores remained statistically significantly (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) different from baseline for all treatment groups. Statistically significantly (<italic>p</italic>&#x02009;&#x02264;&#x02009;0.05) greater reductions in SDS total scores compared with placebo were observed only for patients treated with duloxetine in the HAMD&#x02010;17&#x02009;&#x0003e;&#x02009;22 group and for patients treated with duloxetine or SSRIs in the HAMD&#x02010;17&#x02009;&#x02264;&#x02009;22 group (Table&#x000a0;<xref rid="hup2500-tbl-0002" ref-type="table-wrap">2</xref>).</p><p>When patients were grouped by baseline illness severity measured by MADRS (MADRS &#x02264;30 vs &#x0003e;30), SDS total endpoint scores were statistically significantly (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) different from baseline for all treatment groups; however, no significant differences between treatment groups were found, potentially because of the small sample size (Table&#x000a0;<xref rid="hup2500-tbl-0002" ref-type="table-wrap">2</xref>).</p></sec><sec id="hup2500-sec-0019"><title>Change from baseline in Sheehan Disability Scale individual item scores</title><p>For all three SDS items, each treatment resulted in statistically significantly (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) different endpoint scores compared with baseline, and both treatments with duloxetine and treatment with SSRIs were associated with statistically significantly (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) greater score improvements for all SDS items compared with placebo. No statistically significant differences were observed between treatment with duloxetine and treatment with SSRIs (Table&#x000a0;<xref rid="hup2500-tbl-0002" ref-type="table-wrap">2</xref>).</p><p>When patients were grouped by baseline illness severity (MADRS &#x02264;30 vs &#x0003e;30; HAMD&#x02010;17 &#x02264;22 vs &#x0003e;22), changes from baseline scores remained statistically significant (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) for all treatment groups. Additionally, in patients with more severe depressive symptoms at baseline (HAMD&#x02010;17 score&#x02009;&#x0003e;&#x02009;22), statistically significantly (<italic>p</italic>&#x02009;&#x02264;&#x02009;0.05) greater improvement after treatment with duloxetine was observed for SDS item 1 compared with treatment with SSRIs. No differences between treatment with duloxetine and treatment with SSRIs were observed for SDS items 2 and 3 (Table&#x000a0;<xref rid="hup2500-tbl-0002" ref-type="table-wrap">2</xref>). For patients with less severe depressive symptoms (MADRS&#x02009;&#x02264;&#x02009;30 and HAMD&#x02010;17&#x02009;&#x02264;&#x02009;22), treatment with both duloxetine and SSRIs resulted in statistically significant (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) improvements from baseline for all SDS item scores.</p></sec><sec id="hup2500-sec-0020"><title>Number needed to treat</title><p>At endpoint, 295 (28.7%) patients treated with duloxetine and 212 (25.4%) patients treated with an SSRI had an SDS total score of &#x02264;6, while 71 patients (21.6%) treated by placebo had an SDS total score of &#x02264;6. The <italic>NNT</italic> to reach an SDS total score of &#x02264;6 at last&#x02010;observation&#x02010;carried&#x02010;forward endpoint for the pooled dataset was 14 for duloxetine and 26 for SSRIs.</p></sec><sec id="hup2500-sec-0021"><title>Logistic regression analyses</title><p>At endpoint, 295 (28.7%) patients treated with duloxetine and 212 (25.4%) patients treated with an SSRI had an SDS total score of &#x02264;6 (SDS total score at endpoint &#x0003e;6: duloxetine <italic>n</italic>&#x02009;=&#x02009;625 [60.7%]; SSRIs <italic>n</italic>&#x02009;=&#x02009;546 [65.4%]; missing data: duloxetine <italic>n</italic>&#x02009;=&#x02009;109 [10.6%]; SSRIs <italic>n</italic>&#x02009;=&#x02009;77 [9.2%]). No statistically significant differences between duloxetine and SSRIs were observed when the ORs were examined for reaching an SDS total score of &#x02264;6 (Table&#x000a0;<xref rid="hup2500-tbl-0003" ref-type="table-wrap">3</xref>).</p><table-wrap id="hup2500-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Logistical regression analysis of SDS total scores (&#x02264;6 vs &#x0003e;6) and SDS items 1, 2 and 3 scores (&#x02264;2 vs &#x0003e;2)&#x02014;data from studies HMAYa, HMAYb, HMCR and HMFT; all randomized patients</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" align="left" valign="bottom" colspan="1">Population</th><th rowspan="2" align="center" valign="bottom" colspan="1">Comparison</th><th colspan="2" align="center" valign="bottom" rowspan="1">SDS total (&#x02264;6 vs &#x0003e;6)</th><th colspan="2" align="center" valign="bottom" rowspan="1">Item 1 (&#x02264;2 vs &#x0003e;2)</th><th colspan="2" align="center" valign="bottom" rowspan="1">Item 2 (&#x02264;2 vs &#x0003e;2)</th><th colspan="2" align="center" valign="bottom" rowspan="1">Item 3 (&#x02264;2 vs &#x0003e;2)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody valign="top"><tr><td rowspan="2" align="left" valign="top" colspan="1">All patients</td><td align="left" valign="top" rowspan="1" colspan="1">DLX vs SSRI</td><td align="char" valign="top" rowspan="1" colspan="1">1.2 (0.95, 1.53)</td><td align="char" valign="top" rowspan="1" colspan="1">0.119</td><td align="char" valign="top" rowspan="1" colspan="1">1.2 (0.92, 1.44)</td><td align="char" valign="top" rowspan="1" colspan="1">0.220</td><td align="char" valign="top" rowspan="1" colspan="1">1.2 (0.95, 1.42)</td><td align="char" valign="top" rowspan="1" colspan="1">0.132</td><td align="char" valign="top" rowspan="1" colspan="1">1.1 (0.92, 1.37)</td><td align="char" valign="top" rowspan="1" colspan="1">0.270</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PLB vs SSRI</td><td align="char" valign="top" rowspan="1" colspan="1">0.9 (0.62, 1.32)</td><td align="char" valign="top" rowspan="1" colspan="1">0.613</td><td align="char" valign="top" rowspan="1" colspan="1">0.6 (0.39, 0.82)</td><td align="char" valign="top" rowspan="1" colspan="1">0.003</td><td align="char" valign="top" rowspan="1" colspan="1">0.7 (0.48, 0.94)</td><td align="char" valign="top" rowspan="1" colspan="1">0.019</td><td align="char" valign="top" rowspan="1" colspan="1">0.6 (0.46, 0.88)</td><td align="char" valign="top" rowspan="1" colspan="1">0.007</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">HAMD&#x02010;17&#x02009;&#x02264;&#x02009;22<xref ref-type="fn" rid="hup2500-note-0014">a</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">DLX vs SSRI</td><td align="char" valign="top" rowspan="1" colspan="1">1.3 (0.94, 1.73)</td><td align="char" valign="top" rowspan="1" colspan="1">0.122</td><td align="char" valign="top" rowspan="1" colspan="1">1.1 (0.83, 1.48)</td><td align="char" valign="top" rowspan="1" colspan="1">0.494</td><td align="char" valign="top" rowspan="1" colspan="1">1.2 (0.89, 1.50)</td><td align="char" valign="top" rowspan="1" colspan="1">0.285</td><td align="char" valign="top" rowspan="1" colspan="1">1.1 (0.83, 1.41)</td><td align="char" valign="top" rowspan="1" colspan="1">0.580</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PLB vs SSRI</td><td align="char" valign="top" rowspan="1" colspan="1">0.9 (0.60, 1.39)</td><td align="char" valign="top" rowspan="1" colspan="1">0.684</td><td align="char" valign="top" rowspan="1" colspan="1">0.6 (0.38, 0.87)</td><td align="char" valign="top" rowspan="1" colspan="1">0.009</td><td align="char" valign="top" rowspan="1" colspan="1">0.6 (0.44, 0.92)</td><td align="char" valign="top" rowspan="1" colspan="1">0.016</td><td align="char" valign="top" rowspan="1" colspan="1">0.7 (0.45, 0.94)</td><td align="char" valign="top" rowspan="1" colspan="1">0.022</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">HAMD&#x02010;17&#x02009;&#x0003e;&#x02009;22<xref ref-type="fn" rid="hup2500-note-0014">a</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">DLX vs SSRI</td><td align="char" valign="top" rowspan="1" colspan="1">1.1 (0.76, 1.60)</td><td align="char" valign="top" rowspan="1" colspan="1">0.611</td><td align="char" valign="top" rowspan="1" colspan="1">1.2 (0.86, 1.75)</td><td align="char" valign="top" rowspan="1" colspan="1">0.266</td><td align="char" valign="top" rowspan="1" colspan="1">1.2 (0.86, 1.60)</td><td align="char" valign="top" rowspan="1" colspan="1">0.317</td><td align="char" valign="top" rowspan="1" colspan="1">1.2 (0.86, 1.59)</td><td align="char" valign="top" rowspan="1" colspan="1">0.310</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PLB vs SSRI</td><td align="char" valign="top" rowspan="1" colspan="1">0.9 (0.37, 2.27)</td><td align="char" valign="top" rowspan="1" colspan="1">0.858</td><td align="char" valign="top" rowspan="1" colspan="1">0.5 (0.22, 1.25)</td><td align="char" valign="top" rowspan="1" colspan="1">0.143</td><td align="char" valign="top" rowspan="1" colspan="1">0.9 (0.40, 1.83)</td><td align="char" valign="top" rowspan="1" colspan="1">0.693</td><td align="char" valign="top" rowspan="1" colspan="1">0.6 (0.26, 1.22)</td><td align="char" valign="top" rowspan="1" colspan="1">0.146</td></tr></tbody></table><table-wrap-foot><fn id="hup2500-note-0013"><p>CI, confidence interval; DLX, duloxetine; HAMD&#x02010;17, 17&#x02010;item Hamilton Depression Rating Scale; OR, odds ratio; <italic>p</italic>, <italic>p</italic>&#x02010;value; PLB, placebo; SDS, Sheehan Disability Scale; SSRI, selective serotonin reuptake inhibitor.</p></fn><fn id="hup2500-note-0014"><label>a</label><p>Baseline score.</p></fn></table-wrap-foot></table-wrap><p>Within the group of patients with an HAMD&#x02010;17 baseline score of &#x0003e;22, 109 (26.5%) patients receiving treatment with duloxetine and 93 (24.5%) patients treated with an SSRI had an SDS total score of &#x02264;6 at endpoint (SDS total score at endpoint&#x02009;&#x0003e;&#x02009;6: duloxetine <italic>n</italic>&#x02009;=&#x02009;257 [62.4%]; SSRIs <italic>n</italic>&#x02009;=&#x02009;247 [65.2%]; missing data: duloxetine <italic>n</italic>&#x02009;=&#x02009;46 [11.2%]; SSRIs <italic>n</italic>&#x02009;=&#x02009;39 [10.3%]). Within the group of patients with an HAMD&#x02010;17 baseline score of &#x02264;22, 186 (30.2%) patients receiving treatment with duloxetine and 119 (26.1%) patients treated with an SSRI had an SDS total score of &#x02264;6 at endpoint (SDS total score at endpoint&#x02009;&#x0003e;&#x02009;6: duloxetine <italic>n</italic>&#x02009;=&#x02009;366 [59.5%]; SSRIs <italic>n</italic>&#x02009;=&#x02009;299 [65.6%]; missing data: duloxetine <italic>n</italic>&#x02009;=&#x02009;63 [10.2%]; SSRIs <italic>n</italic>&#x02009;=&#x02009;38 [8.3%]). In both the group of patients with an HAMD&#x02010;17 baseline score of &#x0003e;22 and the group with an HAMD&#x02010;17 baseline score of &#x02264;22, no statistically significant differences between duloxetine and SSRIs were observed when the ORs were examined for reaching an SDS total score of &#x02264;6 (Table&#x000a0;<xref rid="hup2500-tbl-0003" ref-type="table-wrap">3</xref>).</p><p>Similar results were obtained when the ORs were examined for reaching scores of &#x02264;2 for individual SDS items. No statistically significant differences between duloxetine and SSRI treatment groups were observed, neither in the all&#x02010;patients group nor in subgroups divided by HAMD&#x02010;17 baseline score (Table&#x000a0;<xref rid="hup2500-tbl-0003" ref-type="table-wrap">3</xref>).</p></sec><sec id="hup2500-sec-0022"><title>Predictor analyses</title><p>When baseline patient characteristics were analysed to predict functional patient outcome at endpoint, patients with higher SDS total baseline scores (more severe functional impairment) and patients with higher HAMD&#x02010;17 baseline scores (more severe depressive symptoms) at baseline showed lower probability to achieve remission in functional impairment (SDS total score&#x02009;&#x02264;&#x02009;6 or SDS individual item scores&#x02009;&#x02264;&#x02009;2) at endpoint. However, female gender was associated with a statistically significantly higher probability of remission in functional impairment compared with male gender. No significant differences were observed among race, number of previous episodes and the duration of the current episode (Table&#x000a0;<xref rid="hup2500-tbl-0004" ref-type="table-wrap">4</xref>).</p><table-wrap id="hup2500-tbl-0004" xml:lang="en" orientation="portrait" position="float"><label>Table 4</label><caption><p>SDS predictor analysis&#x02014;data from studies HMAYa, HMAYb, HMCR and HMFT; all randomized patients</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="(" span="1"/><thead valign="bottom"><tr><th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">Parameter</th><th rowspan="2" colspan="3" align="center" style="border-bottom:solid 1px #000000" valign="bottom">Comparison</th><th colspan="4" align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Total score&#x02009;&#x02264;&#x02009;6 at endpoint</th><th colspan="4" align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Item 1&#x02009;&#x02264;&#x02009;2 at endpoint</th><th colspan="6" align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Item 2&#x02009;&#x02264;&#x02009;2 at endpoint</th><th colspan="4" align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Item 3&#x02009;&#x02264;&#x02009;2 at endpoint</th></tr><tr style="border-bottom:solid 1px #000000"><th colspan="2" align="center" valign="bottom" rowspan="1">
<italic>p</italic>&#x02010;value</th><th colspan="2" align="center" valign="bottom" rowspan="1">OR (95% CI)</th><th colspan="2" align="center" valign="bottom" rowspan="1">
<italic>p</italic>&#x02010;value</th><th colspan="2" align="center" valign="bottom" rowspan="1">OR (95% CI)</th><th colspan="3" align="center" valign="bottom" rowspan="1">
<italic>p</italic>&#x02010;value</th><th colspan="3" align="center" valign="bottom" rowspan="1">OR (95% CI)</th><th colspan="3" align="center" valign="bottom" rowspan="1">
<italic>p</italic>&#x02010;value</th><th align="center" valign="bottom" rowspan="1" colspan="1">OR (95% CI)</th></tr></thead><tbody valign="top"><tr><td rowspan="3" align="left" valign="top" colspan="1">Study</td><td colspan="3" align="left" valign="top" rowspan="1">HMAYa vs HMFT</td><td colspan="2" align="char" valign="top" rowspan="1">&#x0003c;0.0001</td><td colspan="2" align="char" char="." valign="top" rowspan="1">0.48 (0.33, 0.71)</td><td colspan="2" align="char" valign="top" rowspan="1">&#x0003c;0.0001</td><td colspan="2" align="char" char="(" valign="top" rowspan="1">0.61 (0.42, 0.88)</td><td colspan="3" align="char" valign="top" rowspan="1">&#x0003c;0.0001</td><td colspan="3" align="char" char="(" valign="top" rowspan="1">0.71 (0.51, 0.99)</td><td colspan="3" align="char" valign="top" rowspan="1">&#x0003c;0.0001</td><td align="center" valign="top" rowspan="1" colspan="1">0.81 (0.59, 1.13)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">HMAYb vs HMFT</td><td colspan="2" align="left" valign="top" rowspan="1"/><td colspan="2" align="char" char="." valign="top" rowspan="1">0.74 (0.52, 1.06)</td><td colspan="2" align="left" valign="top" rowspan="1"/><td colspan="2" align="char" char="(" valign="top" rowspan="1">0.84 (0.59, 1.20)</td><td colspan="3" align="left" valign="top" rowspan="1"/><td colspan="3" align="char" char="(" valign="top" rowspan="1">1.04 (0.76, 1.43)</td><td colspan="3" align="left" valign="top" rowspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1.11 (0.81, 1.52)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">HMCR vs HMFT</td><td colspan="2" align="left" valign="top" rowspan="1"/><td colspan="2" align="char" char="(" valign="top" rowspan="1">0.33 (0.23, 0.47)</td><td colspan="2" align="left" valign="top" rowspan="1"/><td colspan="2" align="char" char="(" valign="top" rowspan="1">0.47 (0.34, 0.66)</td><td colspan="3" align="left" valign="top" rowspan="1"/><td colspan="3" align="char" char="(" valign="top" rowspan="1">0.46 (0.34, 0.61)</td><td colspan="3" align="left" valign="top" rowspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.38 (0.28, 0.51)</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Treatment</td><td colspan="3" align="left" valign="top" rowspan="1">DLX vs SSRI</td><td colspan="2" align="char" char="." valign="top" rowspan="1">0.069</td><td colspan="2" align="char" char="(" valign="top" rowspan="1">1.22 (0.96, 1.55)</td><td colspan="2" align="char" valign="top" rowspan="1">0.0002</td><td colspan="2" align="char" char="(" valign="top" rowspan="1">1.16 (0.93, 1.46)</td><td colspan="3" align="char" valign="top" rowspan="1">0.0005</td><td colspan="3" align="char" char="(" valign="top" rowspan="1">1.18 (0.96, 1.44)</td><td colspan="3" align="char" char="." valign="top" rowspan="1">0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1.13 (0.92, 1.38)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">PLB vs SSRI</td><td colspan="2" align="left" valign="top" rowspan="1"/><td colspan="2" align="char" char="(" valign="top" rowspan="1">0.87 (0.61, 1.24)</td><td colspan="2" align="left" valign="top" rowspan="1"/><td colspan="2" align="char" char="(" valign="top" rowspan="1">0.58 (0.41, 0.82)</td><td colspan="3" align="left" valign="top" rowspan="1"/><td colspan="3" align="char" char="(" valign="top" rowspan="1">0.66 (0.48, 0.90)</td><td colspan="3" align="left" valign="top" rowspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.65 (0.48, 0.89)</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">SDS total baseline score</td><td colspan="2" align="char" valign="top" rowspan="1">&#x0003c;0.0001</td><td colspan="2" align="char" char="(" valign="top" rowspan="1">0.92 (0.90, 0.94)</td><td colspan="2" align="char" valign="top" rowspan="1">&#x0003c;0.0001</td><td colspan="2" align="char" char="(" valign="top" rowspan="1">0.76 (0.72, 0.79)</td><td colspan="3" align="char" valign="top" rowspan="1">&#x0003c;0.0001</td><td colspan="3" align="char" char="(" valign="top" rowspan="1">0.84 (0.81, 0.88)</td><td colspan="3" align="char" valign="top" rowspan="1">&#x0003c;0.0001</td><td align="center" valign="top" rowspan="1" colspan="1">0.83 (0.79, 0.86)</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">HAMD&#x02010;17 baseline score</td><td colspan="2" align="char" char="." valign="top" rowspan="1">0.006</td><td colspan="2" align="char" char="(" valign="top" rowspan="1">0.96 (0.94, 0.99)</td><td colspan="2" align="char" valign="top" rowspan="1">0.003</td><td colspan="2" align="char" char="(" valign="top" rowspan="1">0.96 (0.94, 0.99)</td><td colspan="3" align="char" char="." valign="top" rowspan="1">0.001</td><td colspan="3" align="char" char="(" valign="top" rowspan="1">0.96 (0.94, 0.99)</td><td colspan="3" align="char" valign="top" rowspan="1">0.0008</td><td align="center" valign="top" rowspan="1" colspan="1">0.96 (0.94, 0.99)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender</td><td colspan="3" align="left" valign="top" rowspan="1">Female vs male</td><td colspan="2" align="char" char="." valign="top" rowspan="1">0.022</td><td colspan="2" align="char" char="(" valign="top" rowspan="1">1.31 (1.04, 1.65)</td><td colspan="2" align="char" valign="top" rowspan="1">0.001</td><td colspan="2" align="char" char="(" valign="top" rowspan="1">1.45 (1.16, 1.82)</td><td colspan="3" align="char" valign="top" rowspan="1">0.0009</td><td colspan="3" align="char" char="(" valign="top" rowspan="1">1.41 (1.15, 1.72)</td><td colspan="3" align="char" char="." valign="top" rowspan="1">0.006</td><td align="center" valign="top" rowspan="1" colspan="1">1.33 (1.09, 1.62)</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Age</td><td colspan="2" align="char" char="." valign="top" rowspan="1">0.385</td><td colspan="2" align="char" char="(" valign="top" rowspan="1">1.00 (0.99, 1.01)</td><td colspan="2" align="char" valign="top" rowspan="1">0.994</td><td colspan="2" align="char" char="(" valign="top" rowspan="1">1.00 (0.99, 1.01)</td><td colspan="3" align="char" char="." valign="top" rowspan="1">0.308</td><td colspan="3" align="char" char="(" valign="top" rowspan="1">1.00 (1.00, 1.01)</td><td colspan="3" align="char" char="." valign="top" rowspan="1">0.306</td><td align="center" valign="top" rowspan="1" colspan="1">1.00 (1.00, 1.01)</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Race</td><td colspan="3" align="left" valign="top" rowspan="1">African American vs White</td><td rowspan="2" colspan="2" align="char" char="." valign="top">0.310</td><td colspan="2" align="char" char="(" valign="top" rowspan="1">1.10 (0.74, 1.63)</td><td rowspan="2" colspan="2" align="char" valign="top">0.051</td><td colspan="2" align="char" char="(" valign="top" rowspan="1">0.94 (0.64, 1.37)</td><td rowspan="2" colspan="3" align="char" char="." valign="top">0.661</td><td colspan="3" align="char" char="(" valign="top" rowspan="1">1.15 (0.83, 1.58)</td><td rowspan="2" colspan="3" align="char" char="." valign="top">0.666</td><td align="center" valign="top" rowspan="1" colspan="1">1.12 (0.81, 1.55)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Other vs White</td><td colspan="2" align="char" char="(" valign="top" rowspan="1">0.74 (0.48, 1.14)</td><td colspan="2" align="char" char="(" valign="top" rowspan="1">0.59 (0.39, 0.90)</td><td colspan="3" align="char" char="(" valign="top" rowspan="1">0.96 (0.69, 1.35)</td><td align="center" valign="top" rowspan="1" colspan="1">0.93 (0.66, 1.30)</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Number of previous episodes</td><td colspan="3" align="left" valign="top" rowspan="1">&#x02264;2 episodes vs missing</td><td rowspan="2" colspan="2" align="char" char="." valign="top">0.887</td><td colspan="2" align="char" char="(" valign="top" rowspan="1">1.07 (0.59, 1.94)</td><td rowspan="2" colspan="2" align="char" valign="top">0.456</td><td colspan="2" align="char" char="(" valign="top" rowspan="1">1.10 (0.64, 1.89)</td><td rowspan="2" colspan="3" align="char" char="." valign="top">0.734</td><td colspan="3" align="char" char="(" valign="top" rowspan="1">0.94 (0.58, 1.53)</td><td rowspan="2" colspan="3" align="char" char="." valign="top">0.474</td><td align="center" valign="top" rowspan="1" colspan="1">0.81 (0.50, 1.32)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">&#x0003e;2 episodes vs missing</td><td colspan="2" align="char" char="(" valign="top" rowspan="1">1.00 (0.56, 1.81)</td><td colspan="2" align="char" char="(" valign="top" rowspan="1">0.94 (0.55, 1.61)</td><td colspan="3" align="char" char="(" valign="top" rowspan="1">0.88 (0.54, 1.42)</td><td align="center" valign="top" rowspan="1" colspan="1">0.75 (0.47, 1.22)</td></tr><tr><td colspan="22" align="center" valign="top" rowspan="1"/></tr><tr><td colspan="14" align="left" valign="top" rowspan="1">Comparison between treatments for SDS total score&#x02009;&#x02264;&#x02009;6 at endpoint</td><td colspan="3" align="center" valign="top" rowspan="1">Estimate (SE)</td><td colspan="3" align="center" valign="top" rowspan="1">OR</td><td colspan="2" align="center" valign="top" rowspan="1">
<italic>p</italic>&#x02010;value</td></tr><tr><td colspan="14" align="left" valign="top" rowspan="1">DLX vs PLB</td><td colspan="3" align="char" char="(" valign="top" rowspan="1">0.34 (0.17)</td><td colspan="3" align="char" char="." valign="top" rowspan="1">1.40</td><td colspan="2" align="char" char="." valign="top" rowspan="1">0.046</td></tr><tr><td colspan="14" align="left" valign="top" rowspan="1">DLX vs SSRI</td><td colspan="3" align="char" char="(" valign="top" rowspan="1">0.20 (0.12)</td><td colspan="3" align="char" char="." valign="top" rowspan="1">1.22</td><td colspan="2" align="char" char="." valign="top" rowspan="1">0.099</td></tr><tr><td colspan="14" align="left" valign="top" rowspan="1">SSRI vs PLB</td><td colspan="3" align="char" char="(" valign="top" rowspan="1">0.14 (0.18)</td><td colspan="3" align="char" char="." valign="top" rowspan="1">1.15</td><td colspan="2" align="char" char="." valign="top" rowspan="1">0.438</td></tr><tr><td colspan="22" align="center" valign="top" rowspan="1"/></tr><tr><td rowspan="2" colspan="2" align="left" valign="top">Comparison</td><td colspan="5" align="center" valign="top" rowspan="1">SDS item 1 score&#x02009;&#x02264;&#x02009;2 at endpoint</td><td colspan="6" align="center" valign="top" rowspan="1">SDS item 2 score&#x02009;&#x02264;&#x02009;2 At endpoint</td><td colspan="9" align="center" valign="top" rowspan="1">SDS item 3 score&#x02009;&#x02264;&#x02009;2 at endpoint</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Estimate (SE)</td><td colspan="2" align="center" valign="top" rowspan="1">OR</td><td colspan="2" align="center" valign="top" rowspan="1">
<italic>p</italic>&#x02010;value</td><td colspan="2" align="center" valign="top" rowspan="1">Estimate (SE)</td><td colspan="2" align="center" valign="top" rowspan="1">OR</td><td colspan="2" align="center" valign="top" rowspan="1">
<italic>p</italic>&#x02010;value</td><td colspan="3" align="center" valign="top" rowspan="1">Estimate (SE)</td><td colspan="3" align="center" valign="top" rowspan="1">OR</td><td colspan="3" align="center" valign="top" rowspan="1">
<italic>p</italic>&#x02010;value</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">DLX vs PLB</td><td align="char" valign="top" rowspan="1" colspan="1">0.69 (0.17)</td><td colspan="2" align="char" char="." valign="top" rowspan="1">2.00</td><td colspan="2" align="char" char="." valign="top" rowspan="1">&#x0003c;0.0001</td><td colspan="2" align="char" char="(" valign="top" rowspan="1">0.58 (0.15)</td><td colspan="2" align="char" char="." valign="top" rowspan="1">1.79</td><td colspan="2" align="char" char="." valign="top" rowspan="1">0.0001</td><td colspan="3" align="char" char="(" valign="top" rowspan="1">0.55 (0.15)</td><td colspan="3" align="char" char="." valign="top" rowspan="1">1.74</td><td colspan="3" align="char" char="." valign="top" rowspan="1">0.0001</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">DLX vs SSRI</td><td align="char" valign="top" rowspan="1" colspan="1">0.15 (0.12)</td><td colspan="2" align="char" char="." valign="top" rowspan="1">1.16</td><td colspan="2" align="char" char="." valign="top" rowspan="1">0.204</td><td colspan="2" align="char" char="(" valign="top" rowspan="1">0.16 (0.10)</td><td colspan="2" align="char" char="." valign="top" rowspan="1">1.18</td><td colspan="2" align="char" char="." valign="top" rowspan="1">0.115</td><td colspan="3" align="char" char="(" valign="top" rowspan="1">0.12 (0.10)</td><td colspan="3" align="char" char="." valign="top" rowspan="1">1.13</td><td colspan="3" align="char" char="." valign="top" rowspan="1">0.115</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">SSRI vs PLB</td><td align="char" valign="top" rowspan="1" colspan="1">0.54 (0.18)</td><td colspan="2" align="char" char="." valign="top" rowspan="1">1.72</td><td colspan="2" align="char" char="." valign="top" rowspan="1">0.002</td><td colspan="2" align="char" char="(" valign="top" rowspan="1">0.42 (0.16)</td><td colspan="2" align="char" char="." valign="top" rowspan="1">1.52</td><td colspan="2" align="char" char="." valign="top" rowspan="1">0.008</td><td colspan="3" align="char" char="(" valign="top" rowspan="1">0.43 (0.16)</td><td colspan="3" align="char" char="." valign="top" rowspan="1">1.54</td><td colspan="3" align="char" char="." valign="top" rowspan="1">0.008</td></tr></tbody></table><table-wrap-foot><fn id="hup2500-note-0015"><p>CI, confidence interval; DLX, duloxetine; HAMD&#x02010;17, 17&#x02010;item Hamilton Depression Rating Scale; OR, odds ratio; PLB, placebo; SDS, Sheehan Disability Scale; SE, standard error; SSRI, selective serotonin reuptake inhibitor.</p></fn></table-wrap-foot></table-wrap><p>Only patients treated with duloxetine had a statistically significantly (<italic>p</italic>&#x02009;=&#x02009;0.046) higher probability of achieving an SDS total score of &#x02264;6 compared with placebo treatment; no significant differences were observed between treatment with SSRIs and treatment with placebo or between treatment with duloxetine and treatment with SSRIs (Table&#x000a0;<xref rid="hup2500-tbl-0004" ref-type="table-wrap">4</xref>).</p><p>Both patients treated with duloxetine and patients treated with SSRIs had a statistically significantly (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) higher probability to reach scores of &#x02264;2 for individual SDS items at endpoint compared with those treated with placebo (Table&#x000a0;<xref rid="hup2500-tbl-0004" ref-type="table-wrap">4</xref>).</p></sec><sec id="hup2500-sec-0023"><title>Change from baseline in 17&#x02010;item Hamilton Depression Rating Scale scores</title><p>All three treatment groups showed statistically significantly (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) changed HAMD&#x02010;17 scores at endpoint compared with baseline in the overall patient populations and in patients grouped by HAMD&#x02010;17 baseline scores. HAMD&#x02010;17 scores showed statistically significantly (<italic>p</italic>&#x02009;&#x02264;&#x02009;0.05) greater improvement after treatment with duloxetine and after treatment with SSRIs compared with treatment with placebo without significant differences between duloxetine and SSRI treatments (Table&#x000a0;<xref rid="hup2500-tbl-0005" ref-type="table-wrap">5</xref>).</p><table-wrap id="hup2500-tbl-0005" xml:lang="en" orientation="portrait" position="float"><label>Table 5</label><caption><p>Seventeen&#x02010;item Hamilton Depression Rating Scale total scores at endpoint&#x02014;data from studies HMAYa, HMAYb, HMCR and HMFT; all randomized patients</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" align="left" valign="bottom" colspan="1">Population</th><th colspan="2" align="center" valign="bottom" rowspan="1">DLX</th><th colspan="2" align="center" valign="bottom" rowspan="1">SSRI</th><th colspan="2" align="center" valign="bottom" rowspan="1">PLB</th><th align="center" valign="bottom" rowspan="1" colspan="1">DLX vs SSRI</th><th align="center" valign="bottom" rowspan="1" colspan="1">DLX vs PLB</th><th align="center" valign="bottom" rowspan="1" colspan="1">SSRI vs PLB</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">LSMean (SE)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">LSMean(SE)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">LSMean (SE)</th><th align="center" valign="bottom" rowspan="1" colspan="1">LSMean (effect size)</th><th align="center" valign="bottom" rowspan="1" colspan="1">LSMean (effect size)</th><th align="center" valign="bottom" rowspan="1" colspan="1">LSMean (effect size)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">All patients<xref ref-type="fn" rid="hup2500-note-0018">a</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1027</td><td align="char" valign="top" rowspan="1" colspan="1">10.4 (0.2)<xref ref-type="fn" rid="hup2500-note-0021">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">835</td><td align="char" valign="top" rowspan="1" colspan="1">11.2 (0.2)<xref ref-type="fn" rid="hup2500-note-0021">***</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">329</td><td align="char" valign="top" rowspan="1" colspan="1">11.9 (0.3)<xref ref-type="fn" rid="hup2500-note-0021">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.4 (&#x02212;0.1)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;1.7 (&#x02212;0.3)<xref ref-type="fn" rid="hup2500-note-0024">###</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;1.6 (0.3)<xref ref-type="fn" rid="hup2500-note-0024">###</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HAMD&#x02010;17&#x02009;&#x02264;&#x02009;22<xref ref-type="fn" rid="hup2500-note-0019">b</xref>, <xref ref-type="fn" rid="hup2500-note-0020">c</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">615</td><td align="char" valign="top" rowspan="1" colspan="1">10.1 (0.3)<xref ref-type="fn" rid="hup2500-note-0021">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">456</td><td align="char" valign="top" rowspan="1" colspan="1">10.8 (0.3)<xref ref-type="fn" rid="hup2500-note-0021">***</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">263</td><td align="char" valign="top" rowspan="1" colspan="1">11.6 (0.4)<xref ref-type="fn" rid="hup2500-note-0021">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.4 (&#x02212;0.1)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;1.6 (&#x02212;0.3)<xref ref-type="fn" rid="hup2500-note-0024">###</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;1.2 (0.2)<xref ref-type="fn" rid="hup2500-note-0026">#</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HAMD&#x02010;17&#x02009;&#x0003e;&#x02009;22<xref ref-type="fn" rid="hup2500-note-0019">b</xref>, <xref ref-type="fn" rid="hup2500-note-0020">c</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">412</td><td align="char" valign="top" rowspan="1" colspan="1">11.1 (0.4)<xref ref-type="fn" rid="hup2500-note-0021">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">379</td><td align="char" valign="top" rowspan="1" colspan="1">11.8 (0.4)<xref ref-type="fn" rid="hup2500-note-0021">***</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">66</td><td align="char" valign="top" rowspan="1" colspan="1">13.0 (0.8)<xref ref-type="fn" rid="hup2500-note-0021">***</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;0.4 (0.0)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;1.9 (&#x02212;0.3)<xref ref-type="fn" rid="hup2500-note-0026">#</xref>
</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;2.9 (0.5)<xref ref-type="fn" rid="hup2500-note-0025">##</xref>
</td></tr></tbody></table><table-wrap-foot><fn id="hup2500-note-0016"><p>Effect sizes in each model were calculated for LSMean differences, divided by the standard deviation of the residuals provided by the model of this group. Overall LSMean estimates and effect sizes were calculated as a weighted mean of the corresponding estimates in all studies, with weights based on within&#x02010;group variance, assuming a fixed study effect. <italic>p</italic>&#x02010;values were derived from <italic>t</italic>&#x02010;test for LSMean differences.</p></fn><fn id="hup2500-note-0017"><p>DLX, duloxetine; HAMD&#x02010;17, 17&#x02010;item Hamilton Depression Rating Scale; LSMean, least squares mean; <italic>n</italic>, number of affected patients; PLB, placebo; SE, standard error; SSRI, selective serotonin reuptake inhibitor; ANCOVA, analysis of covariance.</p></fn><fn id="hup2500-note-0018"><label>a</label><p>One ANCOVA model was calculated for each study with treatment as fixed effect and baseline HAMD&#x02010;17 total score as covariate.</p></fn><fn id="hup2500-note-0019"><label>b</label><p>One ANCOVA model was calculated for each study with treatment, HAMD total score at baseline (&#x02264;22/&#x0003e;22), and their interaction as fixed effect and baseline HAMD total score as covariate.</p></fn><fn id="hup2500-note-0020"><label>c</label><p>Baseline.</p></fn><fn id="hup2500-note-0021"><label>***</label><p>
<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 versus baseline;</p></fn><fn id="hup2500-note-0022"><label>**</label><p>
<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 versus baseline;</p></fn><fn id="hup2500-note-0023"><label>*</label><p>
<italic>p</italic>&#x02009;&#x02264;&#x02009;0.05 versus baseline;</p></fn><fn id="hup2500-note-0024"><label>###</label><p>
<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 versus comparator;</p></fn><fn id="hup2500-note-0025"><label>##</label><p>
<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 versus comparator;</p></fn><fn id="hup2500-note-0026"><label>#</label><p>
<italic>p</italic>&#x02009;&#x02264;&#x02009;0.05 versus comparator.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="hup2500-sec-0024"><title>Discussion</title><p>In the pooled analyses presented here, most analyses measuring functional improvement in patients with MDD produced similar results after treatment with duloxetine and treatment with SSRIs. Both treatments resulted in statistically significantly greater functional improvements compared with placebo in patients with MDD, as assessed by changes in the SDS total and individual item scores. When patients were grouped by baseline severity of their depressive symptoms, patients with less severe depressive symptoms (HAMD&#x02010;17&#x02009;&#x02264;&#x02009;22) showed statistically significantly greater improvements in SDS total scores compared with placebo, after treatment with both duloxetine and SSRIs. Patients with more severe depressive symptoms (HAMD&#x02010;17&#x02009;&#x0003e;&#x02009;22) displayed statistically significantly greater improvements in SDS total scores compared with placebo only after treatment with duloxetine, although this was not supported by a similar analysis using baseline MADRS scores &#x02264;30 versus &#x0003e;30.</p><p>When individual SDS items were analysed, in patients who displayed more severe depressive symptoms at baseline (HAMD&#x02010;17&#x02009;&#x0003e;&#x02009;22), statistically significantly greater improvement after treatment with duloxetine was observed for SDS item 1 (work/school). Moret and Briley (<xref rid="hup2500-bib-0015" ref-type="ref">2011</xref>) described, previously, that norepinephrine plays an important role in executive functioning with regard to cognition, motivation and intellect; however, additional studies are needed to establish a causal relationship between norepinephrine levels and improvements in certain aspects of executive functioning.</p><p>The <italic>NNT</italic>s in this meta&#x02010;analysis for both the duloxetine and the SSRI groups were higher (less impressive clinically) than reported previously for experimental design studies (Sheehan and Sheehan, <xref rid="hup2500-bib-0027" ref-type="ref">2008</xref>). There may be two reasons for this. First, some of the treatment arms in the fixed&#x02010;dose studies used doses that were too low to achieve good efficacy for some patients. Fixed&#x02010;dose studies also often have treatment arms that use doses that are too high for other patients, increasing the likelihood of dropouts because of adverse events, before good efficacy is achieved. In fixed&#x02010;dose studies, we therefore expect less impressive <italic>NNT</italic>s than in flexible&#x02010;dose designs. Two of the four studies in this meta&#x02010;analysis were fixed&#x02010;dose designs. Second, the doses for the comparator SSRI paroxetine in two of the four studies were not comparable in efficacy with the doses of duloxetine used in those studies. Consequently, when the results of all studies are aggregated, the <italic>NNT</italic> for the SSRIs would be expected to be higher (less impressive) than the <italic>NNT</italic> for duloxetine. Therefore, we recommend caution in interpreting any difference in these <italic>NNT</italic>s as suggesting any difference in efficacy between duloxetine and SSRIs.</p><p>The results presented here agree with those of prior studies that demonstrated statistically significant functional improvements, as measured by SDS, during treatment with duloxetine (Detke <italic>et al</italic>., <xref rid="hup2500-bib-0002" ref-type="ref">2004</xref>; Gaynor <italic>et al</italic>., <xref rid="hup2500-bib-0007" ref-type="ref">2011a</xref>, <xref rid="hup2500-bib-0008" ref-type="ref">2011b</xref>; Mancini <italic>et al</italic>., <xref rid="hup2500-bib-0012" ref-type="ref">2012</xref>) or SSRIs (Detke <italic>et al</italic>., <xref rid="hup2500-bib-0002" ref-type="ref">2004</xref>) compared with placebo in patients with MDD. The current analyses are the first analyses known to the authors to compare the effects of duloxetine versus SSRIs on functional improvement in patients with MDD in a large, pooled dataset. This approach allowed the authors to compare the relative efficacy of a serotonin and norepinephrine reuptake inhibitor (duloxetine) with SSRIs in achieving remission of functional impairment in patients with MDD. As mentioned earlier, norepinephrine is reported to play a role in modulating cognition, motivation and intellect (Moret and Briley, <xref rid="hup2500-bib-0015" ref-type="ref">2011</xref>), while serotonin may influence psychomotor speed (Constant <italic>et al</italic>., <xref rid="hup2500-bib-0001" ref-type="ref">2005</xref>).</p><p>Treatment with duloxetine and treatment with SSRIs resulted in similar rates of study completion, and duloxetine was associated with the highest rate of patients discontinuing the studies because of adverse events. Those findings are consistent with results from a meta&#x02010;analysis that compared treatment response in patients with generalized anxiety disorder among escitalopram, duloxetine, paroxetine, pregabalin, sertraline and venlafaxine XL (National Collaborating Centre for Mental Health commissioned by the National Institute for Health &#x00026; Clinical Excellence, <xref rid="hup2500-bib-0017" ref-type="ref">2011</xref>). In this analysis, duloxetine had the highest probability of response when only patients who did not discontinue pharmacological treatment were analysed because of intolerable side effects; however, it was also associated with the highest risk of discontinuation because of side effects (National Collaborating Centre for Mental Health commissioned by the National Institute for Health &#x00026;Clinical Excellence, <xref rid="hup2500-bib-0017" ref-type="ref">2011</xref>).</p><p>Higher SDS total or HAMD&#x02010;17 baseline scores predicted lower probability of remission in functional impairment defined as SDS total score&#x02009;&#x02264;&#x02009;6 or SDS individual item scores&#x02009;&#x02264;&#x02009;2 at endpoint after treatment with duloxetine or SSRIs; however, female gender was a predictor for higher probability of functional improvement at endpoint. Gender was described previously as a significant prognostic factor for functional remission in patients with MDD (Mancini <italic>et al</italic>., <xref rid="hup2500-bib-0012" ref-type="ref">2012</xref>).</p><p>When treatment assignment was analysed as a predictor of functional improvement, patients treated with duloxetine had a statistically significantly higher probability of achieving an SDS total score of &#x02264;6 compared with patients treated with placebo. No statistically significant differences were observed between treatment with SSRIs and treatment with placebo or between treatment with duloxetine and treatment with SSRIs. Previously, higher baseline severity of depressive symptoms was associated with a higher probability of patients' depressive symptoms to respond to antidepressant treatment, but not to reach remission of depressive symptoms (Riedel <italic>et al</italic>., <xref rid="hup2500-bib-0022" ref-type="ref">2011</xref>).</p><p>A limitation of the analyses presented here is the pooling of data from four studies that used different designs and different study durations, one of which was open label, and which had different primary objectives, introducing potential bias for the results reported here. While all four studies applied similar inclusion and exclusion criteria that resulted in comparable study populations, the study designs were different among the included studies. The open&#x02010;label study did not have a placebo treatment group and did not collect MADRS data, which resulted in reduced sample sizes for the pooled placebo treatment group and for analyses involving MADRS. The relatively small sample size in the placebo group might have affected the statistical power of analyses comparing active treatment versus placebo; however, comparisons between the active treatment and placebo were not the main focus of the analyses presented here. Further, the ratios of race and region among the three treatment groups were different, which might have influenced the observed results. However, the differences between treatment groups with respect to race and region were due to the individual studies being performed in different regions. Therefore, races and regions were comparable between treatment groups within the individual studies, and part of the effect of race and region can be controlled by the study term included into the model. Additional limitations of this meta&#x02010;analytic study are the retrospective and <italic>post hoc</italic> nature of the study, the many statistical comparisons made, the longer duration of the current depressive episode, the longer duration since the first major depressive episode in the SSRI group, and the possibility that the doses of the duloxetine and the SSRI active comparators may not have been comparable in power. Finally, the studies included in this meta&#x02010;analysis were neither designed nor powered to examine differences in functional treatment outcome between duloxetine and SSRIs. Meta&#x02010;analysis is only exploratory, never confirmatory. Any findings in a meta&#x02010;analysis, which is an observational design, must be later tested using experimental designs.</p></sec><sec id="hup2500-sec-0025"><title>Conclusion</title><p>The results presented here provide further evidence that treatment with both duloxetine and SSRIs is associated with greater functional improvement compared with treatment with placebo in patients with MDD, as measured by SDS, with different outcomes depending on baseline symptom severity. The SDS or HAMD&#x02010;17 baseline scores, and female gender, predict greater likelihood of remission in functional impairment at endpoint.</p></sec><sec id="hup2500-sec-0026"><title>Conflict of Interest</title><p>Dr Sheehan has received grant funding support or been affiliated or received honoraria and travel expenses related to lectures/presentations or consultant activities from the following organizations:</p><p>Abbott Laboratories<sup>1,2,3</sup>; Actavis<sup>1</sup>; Ad Hoc Committee, Treatment Drug &#x00026; Assessment Research Review<sup>1</sup>; Alexa<sup>1</sup>; Alza Pharmaceuticals<sup>1</sup>; American Medical Association<sup>2</sup>; American Psychiatric Association Task Force on Benzodiazepine Dependency<sup>1</sup>; American Psychiatric Association Task Force on Treatments of Psychiatric Disorders<sup>1</sup>; American Psychiatric Association Working Group to revise DSM III Anxiety Disorders Section<sup>1</sup>; Anclote Foundation<sup>2</sup>; Anxiety Disorders Resource Center<sup>1</sup>; Anxiety Drug Efficacy Case, U.S. Food &#x00026; Drug Administration<sup>1</sup>; Applied Health Outcomes/xCenda<sup>1</sup>; Apsen Pharma<sup>3</sup>; AstraZeneca<sup>1,2,3</sup>; Avera Pharmaceuticals<sup>1,2</sup>; BioMarin<sup>1</sup>; Bionomics<sup>1</sup>; Boehringer Ingelheim<sup>3</sup>; Boots Pharmaceuticals<sup>3</sup>; Bristol&#x02010;Myers Squibb<sup>1,2,3</sup>; Burroughs Wellcome<sup>2,3</sup>; Cephalon<sup>1</sup>; Charter Hospitals<sup>3</sup>; Ciba Geigy<sup>3</sup>; Committee (RRC) of N.I.M.H. on Anxiety and Phobic Disorder Projects<sup>1</sup>; Connecticut &#x00026; Ohio Academies of Family Physicians<sup>1</sup>; Cortex Pharmaceutical<sup>1</sup>; Council on Anxiety Disorders<sup>1</sup>; CPC Coliseum Medical Center<sup>1</sup>; Cypress Bioscience<sup>1</sup>; Daiichi Sankyo Pharma Development<sup>1</sup>; Daiichi Sumitomo<sup>2</sup>; Dista Products Company<sup>3</sup>; Division of Drugs &#x00026; Technology, American Medical Association<sup>1</sup>; EISAI<sup>1,2</sup>; Eli Lilly<sup>1,2,3</sup>; Excerpta Medica Asia<sup>3</sup>; Faxmed, Inc<sup>1</sup>; Forest Laboratories<sup>1,2</sup>; Glaxo Pharmaceuticals<sup>3</sup>; GlaxoSmithKline<sup>1,2,3</sup>; Glaxo&#x02010;Wellcome<sup>2</sup>; Hikma Pharmaceuticals<sup>3</sup>; Hospital Corporation of America<sup>3</sup>; Humana<sup>3</sup>; ICI<sup>3</sup>; INC Research<sup>1,3</sup>; International Clinical Research (ICR)<sup>2</sup>; International Society for CNS Drug Development (ISCDD)<sup>1</sup>; Janssen Pharmaceutica<sup>1,2,3</sup>; Jazz Pharmaceuticals<sup>1,2</sup>; Kali&#x02010;Duphar<sup>2,3</sup>; Labopharm&#x02010;Angellini<sup>1,2,3</sup>; Layton Bioscience<sup>1</sup>; Lilly Research Laboratories<sup>1</sup>; Lundbeck<sup>1,2,3</sup>; Marion Merrill Dow<sup>3</sup>; McNeil Pharmaceuticals<sup>3</sup>; Mead Johnson<sup>2,3</sup>; Macmillan<sup>3</sup>; MAPI<sup>1</sup>; Medical Outcome Systems<sup>4</sup>; MediciNova<sup>1,2</sup>; Merck Sharp &#x00026; Dohme<sup>2,3</sup>; National Anxiety Awareness Program<sup>1</sup>; National Anxiety Foundation<sup>1</sup>; National Depressive &#x00026; Manic Depressive Association<sup>1</sup>; National Institute of Drug Abuse<sup>2</sup>; National Institutes of Health (NIH)<sup>2</sup>; Neuronetics<sup>1</sup>; NovaDel<sup>1</sup>; Novartis Pharmaceuticals Corp<sup>1,2</sup>; Novo Nordisk<sup>3</sup>; Organon<sup>1,3</sup>; Orion Pharma<sup>1</sup>; Parexel International Corporation<sup>1</sup>; Otsuka<sup>1</sup>; Parke&#x02010;Davis<sup>2,3</sup>; Pfizer<sup>1,2,3</sup>; Pharmacia<sup>1</sup>; Pharmacia &#x00026; Upjohn<sup>1,3</sup>; PharmaNeuroBoost<sup>1,3</sup>; Philadelphia College of Pharmacy &#x00026; Science<sup>1</sup>; Pierre Fabre, France<sup>1</sup>; Quintiles<sup>2</sup>; ProPhase<sup>1</sup>; Rhone Laboratories<sup>3</sup>; Rhone&#x02010;Poulenc Rorer Pharmaceuticals<sup>3</sup>; Roche<sup>1</sup>; Roerig<sup>3</sup>; Sagene Pharma<sup>1</sup>; Sandoz Pharmaceuticals<sup>2,3</sup>; Sanofi&#x02010;Aventis<sup>1,2,3</sup>; Sanofi&#x02010;Synthelabo Recherche/Sanofi&#x02010;Aventis<sup>1,2</sup>; Schering Corporation<sup>3</sup>; Sepracor<sup>1</sup>; Shire Laboratories, Inc<sup>1</sup>; Simon and Schuster<sup>3</sup>; SmithKlineBeecham<sup>1,2,3</sup>; Solvay Pharmaceuticals<sup>1,3</sup>; Sunovion<sup>2,3</sup>; Takeda Pharmaceuticals<sup>1,2,3</sup>; Tampa General Hosp<sup>1</sup>; University of South Florida Psychiatry Center<sup>2</sup>; University of South Florida College of Medicine. TAP Pharmaceuticals<sup>2,3</sup>; Targacept<sup>1</sup>; TGH&#x02010;University Psychiatry Center<sup>3</sup>; Tikvah Therapeutics<sup>1</sup>; Titan Pharmaceuticals<sup>1</sup>; United Bioscience<sup>1,2,3</sup>; The Upjohn Company<sup>1,2,3</sup>; U.S. Congress&#x02010;House of Representatives Committee<sup>1</sup>; USF Friends of Research in Psychiatry, Board of Trustees<sup>1</sup>; Warner Chilcott<sup>2,3</sup>; World Health Organization<sup>1</sup>; Worldwide Clinical Trials<sup>2</sup>; Wyeth&#x02010;Ayerst<sup>1,2,3</sup>; ZARS<sup>1</sup>; Zeneca Pharmaceuticals<sup>2</sup>; Neuronetics<sup>1</sup>
</p><p>1, consultant; 2, grant/research support; 3, lectures/ presentations/royalties; and 4, stockholder.</p><p>Dr Sheehan is the creator of the scale that measures functional impairment (Sheehan Disability Scale) that is the subject of this paper. Dr Sheehan did not receive any payment for the work in preparing this manuscript. Drs Mancini, Wang, Berggren, Cao, Due&#x000f1;as and Yue are full&#x02010;time employees and stockholders of Eli Lilly and Company.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="hup2500-supitem-0001"><caption><p>Supporting info item</p></caption><media xlink:href="HUP-31-53-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="hup2500-sec-0027"><title>Acknowledgements</title><p>The authors thank Dr Alexander Schacht, Eli Lilly and Company, for statistical consultation and Dr Alexandra Heinloth and Ms Maria Rovere, MTSC, both full&#x02010;time employees of inVentiv Health Clinical, LLC, for writing and editorial assistance. Eli Lilly and Company contracted Accovion for statistical services and inVentiv Health Clinical, LLC, for writing and editorial services.</p><p>This work was supported by Lilly Suzhou Pharmaceutical Company Ltd, Shanghai, China, and Eli Lilly and Company.</p></ack><ref-list content-type="cited-references" id="hup2500-bibl-0001"><title>References</title><ref id="hup2500-bib-0001"><mixed-citation publication-type="journal" id="hup2500-cit-0001">
<string-name>
<surname>Constant</surname>
<given-names>EL</given-names>
</string-name>, <string-name>
<surname>Adam</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Gillain</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Seron</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Bruyer</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Seghers</surname>
<given-names>A</given-names>
</string-name>. <year>2005</year>
<article-title>Effects of sertraline on depressive symptoms and attentional and executive functions in major depression</article-title>. <source>Depress Anxiety</source>
<volume>21</volume>: <fpage>78</fpage>&#x02013;<lpage>89</lpage>.<pub-id pub-id-type="pmid">15884090</pub-id></mixed-citation></ref><ref id="hup2500-bib-0002"><mixed-citation publication-type="journal" id="hup2500-cit-0002">
<string-name>
<surname>Detke</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Wiltse</surname>
<given-names>CG</given-names>
</string-name>, <string-name>
<surname>Mallinckrodt</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>McNamara</surname>
<given-names>RK</given-names>
</string-name>, <string-name>
<surname>Demitrack</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Bitter</surname>
<given-names>I</given-names>
</string-name>. <year>2004</year>
<article-title>Duloxetine in the acute and long&#x02010;term treatment of major depressive disorder: a placebo&#x02010; and paroxetine&#x02010;controlled trial</article-title>. <source>Eur Neuropsychopharmacol</source>
<volume>14</volume>: <fpage>457</fpage>&#x02013;<lpage>470</lpage>.<pub-id pub-id-type="pmid">15589385</pub-id></mixed-citation></ref><ref id="hup2500-bib-0003"><mixed-citation publication-type="journal" id="hup2500-cit-0003">
<string-name>
<surname>Due&#x000f1;as</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Brnabic</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Chung</surname>
<given-names>KF</given-names>
</string-name>, <italic>et al.</italic>
<year>2011</year>
<article-title>Frequency of treatment&#x02010;emergent sexual dysfunction and treatment effectiveness during SSRI or duloxetine therapy: 8&#x02010;week data from a 6&#x02010;month observational study</article-title>. <source>Int J Psychiatry Clin Pract</source>
<volume>15</volume>: <fpage>80</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">22121855</pub-id></mixed-citation></ref><ref id="hup2500-bib-0004"><mixed-citation publication-type="journal" id="hup2500-cit-0004">
<string-name>
<surname>Dunn</surname>
<given-names>TW</given-names>
</string-name>, <string-name>
<surname>Vittengl</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Clark</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Carmody</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Thase</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Jarrett</surname>
<given-names>RB</given-names>
</string-name>. <year>2012</year>
<article-title>Change in psychosocial functioning and depressive symptoms during acute&#x02010;phase cognitive therapy for depression</article-title>. <source>Psychol Med</source>
<volume>42</volume>: <fpage>1</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="pmid">21733222</pub-id></mixed-citation></ref><ref id="hup2500-bib-0005"><mixed-citation publication-type="book" id="hup2500-cit-0005">
<collab collab-type="authors">Eli Lilly and Company</collab>
. <article-title>Cymbalta [package insert]</article-title>. <publisher-loc>Indianapolis, IN</publisher-loc>
<year>2014</year>.</mixed-citation></ref><ref id="hup2500-bib-0006"><mixed-citation publication-type="book" id="hup2500-cit-0006">
<collab collab-type="authors">Forest Laboratories, Inc.</collab>
. <article-title>Lexapro [package insert]</article-title>. <publisher-loc>St. Louis, MO</publisher-loc>
<year>2009</year>.</mixed-citation></ref><ref id="hup2500-bib-0007"><mixed-citation publication-type="journal" id="hup2500-cit-0007">
<string-name>
<surname>Gaynor</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Gopal</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>W</given-names>
</string-name>, <italic>et al.</italic>
<year>2011a</year>
<article-title>Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study</article-title>. <source>Curr Med Res Opin</source>
<volume>27</volume>: <fpage>1859</fpage>&#x02013;<lpage>1867</lpage>.<pub-id pub-id-type="pmid">21838410</pub-id></mixed-citation></ref><ref id="hup2500-bib-0008"><mixed-citation publication-type="journal" id="hup2500-cit-0008">
<string-name>
<surname>Gaynor</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Gopal</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Martinez</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Robinson</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Marangell</surname>
<given-names>LB</given-names>
</string-name>. <year>2011b</year>
<article-title>A randomized placebo&#x02010;controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms</article-title>. <source>Curr Med Res Opin</source>
<volume>27</volume>: <fpage>1849</fpage>&#x02013;<lpage>1858</lpage>.<pub-id pub-id-type="pmid">21838411</pub-id></mixed-citation></ref><ref id="hup2500-bib-0009"><mixed-citation publication-type="book" id="hup2500-cit-0009">
<collab collab-type="authors">GlaxoSmithKline</collab>
. <article-title>Paxil [package insert]</article-title>. <publisher-loc>Research Triangle Park, NC</publisher-loc>
<year>2013</year>.</mixed-citation></ref><ref id="hup2500-bib-0010"><mixed-citation publication-type="miscellaneous" id="hup2500-cit-0010">
<string-name>
<surname>Guy</surname>
<given-names>W</given-names>
</string-name>. <year>1976</year>, <article-title>ECDEU assessment manual for psychopharmacology revised</article-title>, 1976 US Department of Health, Education, and Welfare, Bethesda (MD).</mixed-citation></ref><ref id="hup2500-bib-0011"><mixed-citation publication-type="journal" id="hup2500-cit-0011">
<string-name>
<surname>Hamilton</surname>
<given-names>M</given-names>
</string-name>. <year>1960</year>
<article-title>A rating scale for depression</article-title>. <source>J Neurol Neurosurg Psychiatr</source>
<volume>23</volume>: <fpage>56</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">14399272</pub-id></mixed-citation></ref><ref id="hup2500-bib-0012"><mixed-citation publication-type="journal" id="hup2500-cit-0012">
<string-name>
<surname>Mancini</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sheehan</surname>
<given-names>DV</given-names>
</string-name>, <string-name>
<surname>Demyttenaere</surname>
<given-names>K</given-names>
</string-name>, <italic>et al.</italic>
<year>2012</year>
<article-title>Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan Disability Scale: pooled analysis of data from six randomized, double&#x02010;blind, placebo&#x02010;controlled clinical studies</article-title>. <source>Int Clin Psychopharmacol</source>
<volume>27</volume>: <fpage>298</fpage>&#x02013;<lpage>309</lpage>.<pub-id pub-id-type="pmid">22954893</pub-id></mixed-citation></ref><ref id="hup2500-bib-0013"><mixed-citation publication-type="journal" id="hup2500-cit-0013">
<string-name>
<surname>Martinez</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Katon</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Greist</surname>
<given-names>JH</given-names>
</string-name>, <italic>et al.</italic>
<year>2012</year>
<article-title>A pragmatic 12&#x02010;week, randomized trial of duloxetine versus generic selective serotonin&#x02010;reuptake inhibitors in the treatment of adult outpatients in a moderate&#x02010;to&#x02010;severe depressive episode</article-title>. <source>Int Clin Psychopharmacol</source>
<volume>27</volume>: <fpage>17</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="pmid">22027844</pub-id></mixed-citation></ref><ref id="hup2500-bib-0014"><mixed-citation publication-type="journal" id="hup2500-cit-0014">
<string-name>
<surname>Montgomery</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Asberg</surname>
<given-names>M</given-names>
</string-name>. <year>1979</year>
<article-title>A new depression scale designed to be sensitive to change</article-title>. <source>Br J Psychiatry</source>
<volume>134</volume>: <fpage>382</fpage>&#x02013;<lpage>389</lpage>.<pub-id pub-id-type="pmid">444788</pub-id></mixed-citation></ref><ref id="hup2500-bib-0015"><mixed-citation publication-type="journal" id="hup2500-cit-0015">
<string-name>
<surname>Moret</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Briley</surname>
<given-names>M</given-names>
</string-name>. <year>2011</year>
<article-title>The importance of norepinephrine in depression</article-title>. <source>Neuropsychiatr Dis Treat</source>
<volume>7</volume>: <fpage>9</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="pmid">21750623</pub-id></mixed-citation></ref><ref id="hup2500-bib-0016"><mixed-citation publication-type="journal" id="hup2500-cit-0016">
<string-name>
<surname>Nakano</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Baba</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Maeshima</surname>
<given-names>H</given-names>
</string-name>, <italic>et al.</italic>
<year>2008</year>
<article-title>Executive dysfunction in medicated, remitted state of major depression</article-title>. <source>J Affect Disord</source>
<volume>111</volume>: <fpage>46</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">18304646</pub-id></mixed-citation></ref><ref id="hup2500-bib-0017"><mixed-citation publication-type="miscellaneous" id="hup2500-cit-0017">
<collab collab-type="authors">National Collaborating Centre for Mental Health commissioned by the National Institute for Health &#x00026;Clinical Excellence</collab>
. <article-title>The nice guideline on management in primary, secondary and community care</article-title>. <year>2011</year>.</mixed-citation></ref><ref id="hup2500-bib-0018"><mixed-citation publication-type="journal" id="hup2500-cit-0018">
<string-name>
<surname>Oakes</surname>
<given-names>TM</given-names>
</string-name>, <string-name>
<surname>Myers</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Marangell</surname>
<given-names>LB</given-names>
</string-name>, <italic>et al.</italic>
<year>2012</year>
<article-title>Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol</article-title>. <source>Hum Psychopharmacol</source>
<volume>27</volume>: <fpage>47</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">22241678</pub-id></mixed-citation></ref><ref id="hup2500-bib-0019"><mixed-citation publication-type="journal" id="hup2500-cit-0019">
<string-name>
<surname>Papakostas</surname>
<given-names>GI</given-names>
</string-name>. <year>2009</year>
<article-title>Major depressive disorder: psychosocial impairment and key considerations in functional improvement</article-title>. <source>Am J Manag Care</source>
<volume>15</volume>: <fpage>S316</fpage>&#x02013;<lpage>S321</lpage>.<pub-id pub-id-type="pmid">20088627</pub-id></mixed-citation></ref><ref id="hup2500-bib-0020"><mixed-citation publication-type="journal" id="hup2500-cit-0020">
<string-name>
<surname>Papakostas</surname>
<given-names>GI</given-names>
</string-name>, <string-name>
<surname>Fava</surname>
<given-names>M</given-names>
</string-name>. <year>2008</year>
<article-title>Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder</article-title>. <source>Dialogues Clin Neurosci</source>
<volume>10</volume>: <fpage>439</fpage>&#x02013;<lpage>451</lpage>.<pub-id pub-id-type="pmid">19170401</pub-id></mixed-citation></ref><ref id="hup2500-bib-0021"><mixed-citation publication-type="journal" id="hup2500-cit-0021">
<string-name>
<surname>Raskin</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Goldstein</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Mallinckrodt</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Ferguson</surname>
<given-names>MB</given-names>
</string-name>. <year>2003</year>
<article-title>Duloxetine in the long&#x02010;term treatment of major depressive disorder</article-title>. <source>J Clin Psychiatr</source>
<volume>64</volume>: <fpage>1237</fpage>&#x02013;<lpage>1244</lpage>.</mixed-citation></ref><ref id="hup2500-bib-0022"><mixed-citation publication-type="journal" id="hup2500-cit-0022">
<string-name>
<surname>Riedel</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>M&#x000f6;ller</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Obermeier</surname>
<given-names>M</given-names>
</string-name>, <italic>et al.</italic>
<year>2011</year>
<article-title>Clinical predictors of response and remission in inpatients with depressive syndromes</article-title>. <source>J Affect Disord</source>
<volume>133</volume>: <fpage>137</fpage>&#x02013;<lpage>149</lpage>.<pub-id pub-id-type="pmid">21555156</pub-id></mixed-citation></ref><ref id="hup2500-bib-0023"><mixed-citation publication-type="journal" id="hup2500-cit-0023">
<string-name>
<surname>Ryts&#x000e4;l&#x000e4;</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Melartin</surname>
<given-names>TK</given-names>
</string-name>, <string-name>
<surname>Leskel&#x000e4;</surname>
<given-names>US</given-names>
</string-name>, <string-name>
<surname>Sokero</surname>
<given-names>TP</given-names>
</string-name>, <string-name>
<surname>Lestel&#x000e4;&#x02010;Mielonen</surname>
<given-names>PS</given-names>
</string-name>, <string-name>
<surname>Isomets&#x000e4;</surname>
<given-names>ET</given-names>
</string-name>. <year>2005</year>
<article-title>Functional and work disability in major depressive disorder</article-title>. <source>J Nerv Ment Dis</source>
<volume>193</volume>: <fpage>189</fpage>&#x02013;<lpage>195</lpage>.<pub-id pub-id-type="pmid">15729109</pub-id></mixed-citation></ref><ref id="hup2500-bib-0024"><mixed-citation publication-type="journal" id="hup2500-cit-0024">
<string-name>
<surname>Sheehan</surname>
<given-names>DV</given-names>
</string-name>, <string-name>
<surname>Harnett&#x02010;Sheehan</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Spann</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>
<given-names>HF</given-names>
</string-name>, <string-name>
<surname>Prakash</surname>
<given-names>A</given-names>
</string-name>. <year>2011a</year>
<article-title>Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan Disability Scale</article-title>. <source>Int Clin Psychopharmacol</source>
<volume>26</volume>: <fpage>75</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">21102344</pub-id></mixed-citation></ref><ref id="hup2500-bib-0025"><mixed-citation publication-type="journal" id="hup2500-cit-0025">
<string-name>
<surname>Sheehan</surname>
<given-names>DV</given-names>
</string-name>, <string-name>
<surname>Chokka</surname>
<given-names>PR</given-names>
</string-name>, <string-name>
<surname>Granger</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Walton</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Raskin</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sagman</surname>
<given-names>D</given-names>
</string-name>. <year>2011b</year>
<article-title>Clinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetine</article-title>. <source>Hum Psychopharmacol</source>
<volume>26</volume>: <fpage>242</fpage>&#x02013;<lpage>251</lpage>.<pub-id pub-id-type="pmid">21681815</pub-id></mixed-citation></ref><ref id="hup2500-bib-0026"><mixed-citation publication-type="journal" id="hup2500-cit-0026">
<string-name>
<surname>Sheehan</surname>
<given-names>DV</given-names>
</string-name>, <string-name>
<surname>Harnett&#x02010;Sheehan</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Raj</surname>
<given-names>BA</given-names>
</string-name>. <year>1996</year>
<article-title>The measurement of disability</article-title>. <source>Int Clin Psychopharmacol</source>
<volume>11</volume>(<issue>Suppl 3</issue>): <fpage>89</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">8923116</pub-id></mixed-citation></ref><ref id="hup2500-bib-0027"><mixed-citation publication-type="journal" id="hup2500-cit-0027">
<string-name>
<surname>Sheehan</surname>
<given-names>KH</given-names>
</string-name>, <string-name>
<surname>Sheehan</surname>
<given-names>DV</given-names>
</string-name>. <year>2008</year>
<article-title>Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale</article-title>. <source>Int Clin Psychopharmacol</source>
<volume>23</volume>: <fpage>70</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">18301121</pub-id></mixed-citation></ref><ref id="hup2500-bib-0028"><mixed-citation publication-type="journal" id="hup2500-cit-0028">
<string-name>
<surname>Snyder</surname>
<given-names>HR</given-names>
</string-name>. <year>2013</year>
<article-title>Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta&#x02010;analysis and review</article-title>. <source>Psychol Bull</source>
<volume>139</volume>: <fpage>81</fpage>&#x02013;<lpage>132</lpage>.<pub-id pub-id-type="pmid">22642228</pub-id></mixed-citation></ref><ref id="hup2500-bib-0029"><mixed-citation publication-type="journal" id="hup2500-cit-0029">
<string-name>
<surname>van der Werff</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Verboom</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Penninx</surname>
<given-names>BW</given-names>
</string-name>, <string-name>
<surname>Nolen</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Ormel</surname>
<given-names>J</given-names>
</string-name>. <year>2010</year>
<article-title>Explaining heterogeneity in disability associated with current major depressive disorder: effects of illness characteristics and comorbid mental disorders</article-title>. <source>J Affect Disord</source>
<volume>127</volume>: <fpage>203</fpage>&#x02013;<lpage>210</lpage>.<pub-id pub-id-type="pmid">20594596</pub-id></mixed-citation></ref><ref id="hup2500-bib-0030"><mixed-citation publication-type="journal" id="hup2500-cit-0030">
<string-name>
<surname>Weinstock</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Keitner</surname>
<given-names>GI</given-names>
</string-name>, <string-name>
<surname>Ryan</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Solomon</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>IW</given-names>
</string-name>. <year>2006</year>
<article-title>Family functioning and mood disorders: a comparison between patients with major depressive disorder and bipolar I disorder</article-title>. <source>J Consult Clin Psychol</source>
<volume>74</volume>: <fpage>1192</fpage>&#x02013;<lpage>1202</lpage>.<pub-id pub-id-type="pmid">17154748</pub-id></mixed-citation></ref></ref-list></back></article>